Pain in rheumatoid arthritis : bone and neuroinflammation-associated mechanisms by Rudjito, Resti
From Department of Physiology and Pharmacology 
Karolinska Institutet, Stockholm, Sweden 
PAIN IN RHEUMATOID ARTHRITIS  






All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Universitetsservice US-AB, 2021 
© Resti Rudjito, 2021 
ISBN 978-91-8016-232-6  
Cover illustration: “Joint Pain” is the author’s artistic interpretation of pain in the joint  
Pain in rheumatoid arthritis  
Bone and neuroinflammation-associated mechanisms 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.)  
By 
Resti Rudjito 
The thesis will be defended in public at CMM Lecture Hall (L8:00, Karolinska University 
Hospital) 
 




Professor Camilla Svensson 
Karolinska Institutet 
Dept. of Physiology and Pharmacology 
 
Co-supervisor(s): 
Professor Chantal Chenu 
Royal Veterinary College 
Dept. of Comparative Biomedical Sciences 
 
Professor Helena Erlandsson Harris 
Karolinska Institutet 
Dept. of Medicine 
 
Professor Juan Miguel Jimenez Andrade 
Autonomous University of Tamaulipas 
Multidisciplinary Academic Unit  
Reynoza-Aztlan  
Opponent: 
Professor Jason McDougall 
Dalhousie University 
Dept. of Pharmacology 
 
Examination Board: 
Professor Hermona Soreq 
Hebrew University of Jerusalem 
Dept. of Biological Chemistry 
 
Associate Professor Andrei Chagin 
Karolinska Institutet 
Dept. of Physiology and Pharmacology 
 
Assistant Professor Shafaq Sikandar 
Queen Mary University of London 








































POPULAR SCIENCE SUMMARY OF THE THESIS 
 
Hitting your elbow against a wall. Touching a hot stove with your hands. Sitting in front of the 
computer all day. What do they all have in common? These situations cause pain. Pain is a 
signal in your body that something is wrong. The capacity to feel pain serves as a guide to 
avoid danger and to allow recovery if injury or inflammation has already occurred.  
Imagine, however, if pain still exists even if the damage has been fixed. This type of pain no 
longer provides useful function and instead creates health concerns. In rheumatoid arthritis 
(RA), which is commonly presented as a disease of joint inflammation, a considerable number 
of patients still report pain despite responding well to drugs that aim to reduce inflammation. 
It is rather baffling that inflammation in RA do not always equal to pain and this phenomenon 
is still a mystery to scientists. Extensive research is now ongoing to develop more effective 
painkillers for these patients. Using an animal model of RA, this thesis explores additional 
mechanisms that can explain persistent pain in RA with the hope of finding new targets for 
treatments.  
First, the important contribution of the bone environment, especially cells called the osteoclasts 
to pain, were demonstrated. The main function of osteoclasts are to degrade bones and while 
there are reports showing that this action can lead to pain, the work presented here revealed 
that osteoclasts can also induce pain by regulating blood vessels and nerve fibers in the bone. 
Importantly, through this mechanism drugs that inhibit osteoclast activity can reduce pain.  
Second, the involvement of molecules that can maintain the system that drives pain in RA was 
determined. The antirheumatic drug baricitinib is known to dampen joint inflammation by 
targeting a signaling pathway called the JAK/STAT pathway. Instead, it was revealed here that 
this drug reduces pain by targeting other molecular interactions, known as AAK1/AP2M1 axis. 
In addition to this, the role of another inflammatory molecule called HMGB1 in regulating pain 
in RA was carefully characterized. Interestingly, the actions of this molecule was observed to 
be different in male versus female mice, which indicate sex differences in pain mechanisms.  
Together, three alternative mechanisms for chronic pain in RA have been proposed in this 
thesis, with the added message that these mechanisms may work differently in males and 






RINGKASAN ILMIAH POPULER DISERTASI 
 
Apa kesamaan diantara siku yang terbentur dinding, memegang kompor panas, dan duduk di 
depan komputer seharian? Semua kejadian tersebut membuat kita merasa nyeri. Rasa nyeri 
adalah tanda yang dikirim tubuh kita atas sesuatu yang tidak lazim. Kemampuan untuk 
merasakan nyeri sangat penting agar tubuh kita dapat menghindari bahaya dan memfasilitasi 
pemulihan saat terjadi cedera atau inflamasi. 
Namun bayangkan, jika kita masih merasa nyeri walau cedera yang diderita telah lama sembuh. 
Alih-alih berguna, rasa nyeri semacam ini malah menjadi gangguan kesehatan. Contohnya, 
para penderita penyakit rematik atau artritis reumatoide. Keluhan rasa nyeri seringkali 
ditemukan pada pasien walaupun mereka telah merespon obat anti-inflamasi dengan baik. 
Inflamasi pada para penderita artritis tidak serta merta menyebabkan rasa nyeri, sehingga ini 
masih membuat para saintis kebingungan. Saat ini, para saintis tengah berusaha keras untuk 
mengembangkan obat pereda nyeri yang lebih efektif bagi penderita artritis. Dengan 
menggunakan hewan uji coba, disertasi ini berusaha menguak mekanisme dibalik nyeri 
tersebut, dan menemukan target baru untuk pengobatan. 
Pertama, disertasi ini mendemonstrasikan peran tulang, terutama sel osteoklas, pada 
kemunculan rasa nyeri. Penelitian sebelumnya menunjukkan bahwa osteoklas dapat 
menyebabkan rasa nyeri pada saat melakukan proses peremajaan tulang. Disertasi ini 
menemukan bahwa rasa nyeri tersebut dapat ditimbulkan oleh osteoklas dengan cara mengatur 
kinerja sel-sel syaraf dan pembuluh darah di sekitar tulang. Penemuan ini berpotensi menjadi 
mekanisme baru bagi obat pereda nyeri melalui inhibisi aktivitas osteoklas. 
Kedua, disertasi ini mengeksplorasi keterlibatan molekul-molekul yang umunya berfungsi 
untuk mengatur proses peradangan dalam mempertahankan rasa nyeri. Obat anti-rematik 
barictinib telah diketahui dapat menekan inflamasi melalui jalur sinyal JAK/STAT. Disertasi 
ini menunjukkan bahwa sebenarnya barictinib menyasar interaksi molekuler lain, yang dikenal 
sebagai AAK1/AP2M1. Selain itu, peran molekul lain, HMGB1, dalam regulasi rasa nyeri 
pada penderita penyakit rematik juga digambarkan dalam disertasi ini. Menariknya, peran 
molekul ini dapat berbeda pada pria dan wanita. 
Secara keseluruhan, disertasi ini membahas tiga mekanisme alternatif penyebab nyeri kronis 







Pain is often the primary reason patients with rheumatoid arthritis (RA) seek medical care. 
Despite effective disease control with currently available disease modifying antirheumatic 
drugs (DMARDs), there are still hurdles to overcome as a significant proportion of patients 
still report continuous pain. This suggests that the relationship between joint inflammation and 
pain severity is not linear. Currently few effective pain treatments for RA are available, which 
leads to individual and societal burden. Understanding the regulation of chronic pain in RA is 
thus vital to identify new drug targets and improve therapeutical strategies. This thesis explores 
alternative mechanisms of pain in RA with a specific focus on bone and neuroinflammation-
associated mechanisms.   
In Paper I, the contribution of osteoclasts to pain mechanisms was characterized in the 
collagen antibody-induced arthritis (CAIA) model. As previously reported, CAIA induces 
transient joint inflammation and persistent mechanical hypersensitivity that outlasts active 
inflammatory state. Herein, local bone erosion was detected in the calcaneus during both 
inflammatory and late phases of the CAIA model. Interestingly, while osteoclast activity was 
prominently increased during the inflammatory phase, pain-like behavior was reversed by two 
different osteoclast inhibitors in the late phase. In order to understand the contribution of 
osteoclast activity in nociceptive mechanisms, bone vascularization and innervation were 
examined. Both vascular and nerve densities were increased in the calcaneus during 
inflammation, but surprisingly remained elevated in the late phase despite resolution of joint 
inflammation. Notably, the CAIA-induced changes in bone, vascular and nerve densities in the 
late phase were attenuated by osteoclast-blocking agents correlating with suppression of 
osteoclast-derived angiogenic and neurogenic factors, such as netrin-1. Blockade of netrin-1 
activity reversed CAIA-induced hypersensitivity in the late phase. Collectively, these findings 
suggest that the pronociceptive role of osteoclasts is not entirely dependent of their resorbing 
actions and that osteoclast inhibitors are effective in alleviating pain during the refractive phase 
of RA.  
Janus kinase/signal transducers and activators of transcription (JAK/STAT) inhibitors 
represent a new class of DMARDs. In Paper II, the antinociceptive effects of the JAK1/2 
inhibitor baricitinib on the CAIA model as well as the underlying mechanisms were 
determined. In this study, baricitinib produced reversal effects on CAIA-induced pain-like 
behavior, which was more pronounced in the late phase of the model. Importantly, the 
antinociceptive properties of baricitinib in the CAIA model do not completely covary with its 
anti-inflammatory effects. Intriguingly, no sign of JAK/STAT activation was detected in the 
dorsal root ganglia (DRGs) or spinal cords of CAIA-subjected mice, thus prompting other 
signaling pathways targeted by baricitinib to be explored. The effect of baricitinib on AAK1 
activity was examined as this pathway was recently identified to be an additional target of 
baricitinib. mRNA levels of Aak1 and its downstream target Ap2m1 as well as phosphorylation 
and total protein of AP2M1 were upregulated in DRGs from the late phase of the CAIA model. 
Baricitinib treatment was able to normalize phosphorylation and total protein levels of AP2M1. 
Taken together, our data suggest that baricitinib may exert its antinociceptive effects through 
modulation of AAK1 rather than JAK/STAT signaling in the phase of refractive arthritis-
induced pain. 
Paper III and IV delineated the role of peripheral and spinal high mobility group box 1 
(HMGB1) in arthritis-induced pain and if the pronociceptive actions of HMGB1 is sex-
dependent. In Paper III, blocking the activity of HMGB1 in the periphery was shown to 
alleviate CAIA-induced pain-like behavior in male but not female mice. Interestingly, local 
injection of Toll-like receptor (TLR)4-activating disulfide HMGB1 induced mechanical 
hypersensitivity in both sexes, but was associated with more pronounced contribution of 
immune cells in males compared to females. CAIA induction has been associated with 
activation of microglia in the spinal cord. In Paper IV, disrupting microglial activity was 
shown to prevent development of disulfide HMGB1-induced pain-like behavior in male but 
not female mice. To further explore sex-specific differences, global spinal protein expression 
was examined using liquid chromatography-mass spectrometry. Surprisingly, several 
antinociceptive and anti-inflammatory proteins were elevated in only male mice that received 
the microglial inhibitor minocycline, some of which modulate protein activation cascade that 
converges on proteinase-activated receptor (PAR)2. Targeting the identified proteins 
individually, however, did not produce robust antinociceptive effects as minocycline. Overall, 
these studies demonstrate the important aspects of sex and cellular location in the contribution 
of peripheral and spinal HMGB1 and TLR4 to arthritis-induced pain. 
In summary, this thesis has described three additional mechanisms of RA-induced pain. The 
findings suggest the involvement of osteoclasts, AAK1/AP2M1 and HMGB1 in mediating 
CAIA-induced hypersensitivity, particularly in the refractive state of the model. In addition, 
this work has highlighted the importance of mapping sex dimorphism and the prospective that 
pain relief is achieved differently in different sexes. Although more research are warranted in 
order to decipher the exact mechanisms that drive and maintain chronic pain in RA, this thesis 
has provided interesting mechanistic insights with respect to the bone environment and 
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Chronic pain is one of the most under-recognized and under-treated conditions in modern 
medicine. It is associated with high healthcare costs and societal burden compounded by the 
loss in productivity due to reduced activity, sick leave, fatigue, anxiety and depression (1, 2). 
Failure to address that chronic pain is a serious health concern has resulted in poor pain 
management, substance abuse and inadequate drug development. A large-scale survey on 
chronic pain conducted in Europe showed that around 20% of the adult populations suffer from 
chronic pain, with higher prevalence in women and in which 50% of the cases are related to 
musculoskeletal diseases, such as fibromyalgia, low-back pain, osteoarthritis and rheumatoid 
arthritis (RA) (3). A follow-up survey reported of a huge treatment gap for chronic pain in 
many European countries, largely due to lack of early diagnosis and timely intervention (4). 
Chronic pain has thus been widely acknowledged by the scientific community as not merely a 
symptom of a disease, but as a disease itself, which requires unique treatment strategies (1). 
Therefore, there is an urgent need to advance our understanding of mechanisms regulating 
chronic pain to underpin novel drug targets and improve therapies.  
RA is a chronic autoimmune disease marked by symptoms of joint inflammation and pain, 
which adversely affect physical and social function (5). In fact, patients consistently rate pain 
relief as one of their higher priorities. Although pain in RA is classically viewed as 
inflammatory, increasing evidence shows that pain can be refractive and constantly present 
even after optimal control of the disease activity with antirheumatic drugs. This is likely due to 
the multifactorial nature of pain that is only partly dependent on inflammation (6). For example, 
the contribution of structural changes to the joint environment has been suggested in non-
inflammatory RA pain. Though the underlying mechanisms are still not clear, mounting data 
point to the important role of the bone-resorbing cells known as osteoclasts in nociception and 
the possibility that these cells can be targets for pain therapy (7, 8).  
Neurochemical changes in the joint and the sensory nervous system are also important aspects 
of RA that may underlie non-inflammatory pain mechanisms. Neuroinflammatory factors, such 
as cytokines, mediate peripheral sensitization that leads to increased pain. Persistent afferent 
input from these factors can also lead to altered central pain processing thus promoting 
enhanced pain sensitivity (9, 10). Therefore, targeting upstream and downstream signaling 
pathways in specific cell types or factors that regulate cytokine production and activity may 
therefore provide beneficial effects for pain.  
In recent years, there has been a growing number of preclinical studies showing sex differences 
in pain mechanisms, including RA-induced pain. While this is not surprising as it is recognized 
that sex differences exist in human pain conditions (11), it has significantly challenged the field 
as the use of male rodents is overrepresented compared to females in preclinical research. Much 
of the sex-specific studies on pain have been focused on the interplay with the immune system. 
For instance, it has been shown that male and female rodents utilize different immune cells to 
 
2 
modulate pain (12, 13), though some argue that pain regulation does not always depend on one 
cell type for each sex but may be related to the pain condition in question (14). Together, this 
shows that more studies are needed to uncover the biological basis for sex differences in pain.  
Pain in RA can arise from multiple mechanisms. This thesis explores alternative mechanisms 
of pain in RA using experimental models that mimic clinical features of RA. The works 
presented here are focused on the role of the osteoclasts as well as neuroinflammation-
associated mechanisms potentially driven by either the Janus kinase/signal transducers and 
activators of transcription factor (JAK/STAT) signaling pathway or high mobility group box 1 
(HMGB1) protein with the goal of finding potential new therapeutical targets. In addition, sex 
differences in pain are examined in order to gain more insights whether there is a need for sex-





















2 LITERATURE REVIEW 
 
2.1 THE BIOLOGY OF PAIN 
According to the International Association for the Study of Pain (IASP), pain is defined as “an 
unpleasant sensory and emotional experience associated with, or resembling with, actual or 
potential tissue damage” (15). The sensation of pain, often referred as acute or adaptive pain, 
serves as the body’s warning system to sickness and injury, and promotes healing responses in 
injured tissues. However, under some circumstances, pain can persist or reoccur, outlasting its 
protective function and becomes debilitating, and this is defined as chronic or maladaptive pain 
(16).  
 
2.1.1 The nociceptive system 
Nociception is the process by which painful stimuli are detected by a subpopulation of 
peripheral nerve fibers called nociceptors (17). Electrophysiological recordings show that 
nociceptors can be activated by painful noxious stimuli, such as pressure, heat, or chemical 
irritants, but not by innocuous stimuli, such as warmth or light touch (18). Nociceptors can be 
classified into two major groups based on their diameter, degree of myelination and conduction 
velocity. Small sized, unmyelinated C fibers are 0.2-1.5 µm in diameter and trigger unlocalized, 
slow pain at a conduction velocity of 0.5-2 m/s. In contrast, medium sized, myelinated Ad 
fibers, which are 1-5 µm in diameter, elicit localized, fast pain at a higher conduction velocity 
of 5-35 m/s due to the myelination of the fibers. As a result, pain comes in two phases: a rapid, 
acute, sharp pain followed by a delayed, more diffused, dull pain, consequent to the activation 
of Ad and C fibers, respectively (16). Ad fibers are subdivided into two main classes: Type I 
responds to both mechanical and chemical stimuli with a relatively high heat threshold (>50oC) 
response, while Type II has a much higher mechanical threshold but lower heat threshold than 
Type I. In addition, C fibers are also heterogenous, in that they include a population sensitive 
to both thermal and mechanical stimuli. C fibers can also be categorized based on their 
molecular properties, such as the so-called peptidergic C fibers that release neuropeptides, 
calcitonin-gene related peptide (CGRP), substance P and express tropomyosin kinase receptor 
A (TrkA) for nerve growth factor (NGF). The non-peptidergic population of C fibers notably 
stain positive for isolectin B4 (IB4) and express the purinergic receptor subtype for ATP, P2X3 
(9). With recent advances in single cell sequencing technology, it has been demonstrated that 
nociceptors display distinct transcriptional states that may be altered upon tissue injury (19, 
20). 
Primary afferent fibers are pseudo-unipolar, in which a common axon that connects to the cell 
body branches into central and peripheral terminals. The cell bodies of nociceptors are located 
in the dorsal root ganglia (DRGs), except for sensory nerves innervating the face, which reside 
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in the trigeminal ganglion (9). When nociceptors are activated by noxious stimuli, the stimulus 
is converted into action potentials, which is conducted from the periphery to the central 
terminal. Primary afferent fibers project into the dorsal horn of the spinal cord, wherein 
different subtypes project into distinct laminae. Ad fibers project to laminae I and V, while C 
fibers project more superficially to laminae I and II (9). C fibers exhibit unique projection 
patterns with peptidergic C fibers terminating within lamina I and the most dorsal part of lamina 
II and non-peptidergic C fibers projecting into the deeper, mid-region of lamina II (21). These 
fibers make synaptic contact with interneurons and projection neurons in the spinal cord, which 
then convey the information to the centers in the brain. Projection neurons from lamina I 
innervate the parabrachial nucleus (22) and periaqueductal grey (23) in the brainstem, and thus 
engage in the descending pain pathway. By contrast, projection neurons from lamina V mainly 
project to the thalamus and various cortical regions, which attribute to the affective component 
of the pain experience (24).  
 
2.1.2 Peripheral and central sensitization 
While nociception describes the neural process of encoding noxious stimuli, sensitization refers 
to the condition in which there is an enhancement of neuronal function and is a common feature 
of chronic pain. This can result in hyperalgesia, which is an exaggerated reaction to a stimulus 
that is normally painful and allodynia, which is pain response to non-noxious stimuli. 
Typically, sensitization is divided into two different types, peripheral and central sensitization 
(9, 10).  
Peripheral sensitization is defined as a heightened sensitivity at the peripheral nerve endings. 
This usually occurs after peripheral tissue inflammation and injury due to pain-inducing factors 
being released by nociceptors and non-neuronal cells (e.g. immune cells, endothelial cells, 
fibroblasts and keratinocytes). Common examples of factors that activate peripheral 
sensitization are cytokines and chemokines, which subsequently stimulate nociceptors since it 
has been reported that nociceptors express various receptors for cytokines and chemokines 
(25). Indeed, intra-articular injection of tumor necrosis factor (TNF) (26), interleukin (IL)-1b 
(27), IL-6 (28) or IL-17 (29) led to an increased responses of joint nociceptors in rodents. Other 
chemical mediators of peripheral sensitization include growth factors such as NGF, 
prostaglandins, neuropeptides, substance P and lipids. In response to these algesic mediators, 
the threshold for nociceptors to generate action potentials are reduced, and this leads to 
enhanced pain sensitivity (25).  
Central sensitization describes the circumstance in which there is amplification of pain by the 
central nervous system (CNS) (30). While originally thought to be a consequence of ongoing 
nociceptive signaling in the periphery, it is increasingly known that central sensitization may 
occur without tissue injury or inflammation. Central sensitization has been identified in most 
pain conditions, and may play a fundamental role in the widespread pain observed in patients 
with fibromyalgia (31). It occurs mainly in the dorsal horn of the spinal cord, whereby the 
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spinal neurons exhibit a reduction in the threshold for activation and an augmented pain 
response. Different processes facilitate central sensitization. For example, persistent 
nociceptive inputs from the periphery induces activation of glutamatergic signaling and spinal 
glial cells, microglia and astrocytes (31). Spinal microglia and astrocytes monitor the CNS 
parenchyma to maintain homeostasis, but in response to stress or injury these cells are activated 
and secrete factors that contribute to central sensitization by amplifying excitatory and 
decreasing inhibitory currents (32). The majority of these findings is, however, based on animal 
studies and it is important to take into account the difficulties of translating them into different 
human pain conditions.  
 
2.1.3 Bone pain 
2.1.3.1 Osteoclasts and pain 
Recent advances have focused on delineating potential mechanisms driving pain that may arise 
from the skeletal structure, often referred to as bone pain, such as over-activation of bone 
remodeling or changes in innervation of the skeleton. The majority of musculoskeletal 
disorders that exhibit bone pain often show enhanced bone resorption. This notion led many to 
hypothesize that osteoclasts, which are the cells that degrade bones, play a role in regulating 
pain mechanisms. Indeed, osteoclasts have been shown to be significantly increased in number 
and are over-activated to destroy bones in several bone pain conditions (7, 33, 34). In addition, 
clinical evidence shows that several osteoclast inhibitors such as bisphosphonates (35) and 
calcitonin (36) are able to reduce pain in patients with cancer and osteoporosis. Increasing data 
in experimental animal studies have also shown the analgesic capabilities of various osteoclast 
inhibitors (Table 1). Interestingly, several studies revealed that osteoclast inhibition led to 
antinociception in pain models without overt bone pathology (37-39). This suggests that 
pronociceptive properties of osteoclasts are not necessarily coupled to bone erosion or that the 
osteoclast inhibitors have off-target effects.  
Osteoclast differentiation is triggered by osteoblasts’ surface-bound receptor activator of 
nuclear factor-kappa B ligand (RANKL), which binds to its receptor on osteoclast precursor 
cells. Mature osteoclasts resorb bones by attaching to the surface and then secreting protons 
through the plasma membrane a3 isoform vacuolar-H+-ATPase (V-ATPase), which creates an 
acidic environment (pH range = 4.0-6.0) (40, 41). Acidification is necessary for bone mineral 
solubilization and matrix degradation, however protons are also known to be potent pain-
inducing mediators (9). Previous studies reported that acid-sensing receptors, the transient 
receptor potential channel vanilloid subfamily member 1 (TRPV1) and the acid sensing ion 
channel 3 (ASIC3), are found to be expressed in the sensory neurons innervating bones (34). 
TRPV1 is activated by pH values <6.0 (42), which is similar to the pH under the ruffled border 
(40). In contrast, ASIC3 is sensitive to milder pH between 6.5 and 7.3 (43), which is equivalent 
to the pH of the bone environment affected by metastatic cancer (44). In accordance, inhibition 
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of V-ATPase (bafilomycin A1) and/or ASIC3 (APETx2) abrogated pain-related behavior in 
experimental models of bone pain (33, 45).  
 
Table 1 List of osteoclast inhibitors that show antinociceptive effects in experimental models of pain 




Pain assessment References 
Acute pain models  
-i.pl. α,β-methylene ATP 


















G6PI-induced arthritis Zoledronate i.p. Thermal (46) 
Zymosan-induced arthritis Risedronate s.c. Weight bearing (47) 



























Bone metastasis OPG-Fc s.c. Mechanical (53) 
Osteoporosis Alendronate s.c. Mechanical, thermal, 
locomotion 
(54-56) 













G6PI: glucose-6-phosphate isomerase; CFA: Complete Freund’s Adjuvant; OPG-Fc: Osteoprotegerin-Fc; CRPS: 
Complex Regional Pain Syndrome; CCI: chronic constriction injury; i.pl.: intraplantar; s.c.: subcutaneous; i.p.: 
intraperitoneal; p.o.: peroral 
 
While osteoclasts are mainly associated with bone resorption, emerging reports show a 
multifunctional role of osteoclasts in pain signaling. This includes the ability of osteoclasts to 
secrete inflammatory factors (e.g. IL-8, TNF), which induces nociception by binding to their 
corresponding receptors on sensory neurons (7, 57). In addition, osteoclasts release axonal 
guidance molecules such as semaphorin 4D (SEMA4D) and netrin-1 (8, 58). Although these 
factors are known to be important for bone remodeling, netrin-1 was reported to induce bone 
innervation and hypersensitivity in models of osteoarthritis and lumbar spine instability (8, 59). 
Furthermore, osteoclasts are also known to secrete angiogenic factors, for example platelet-
derived growth factor BB (PDGF-BB) (60). While the capability of osteoclasts to modulate 
angiogenesis has not been associated with nociceptive mechanisms, the presence of blood 
vessels is crucial for neuronal growth and may thus indirectly contribute to innervation and 
pain. Interestingly, application of exogenous RANKL did not induce pain-like behavior in mice 
indicating that activation of osteoclasts alone does not evoke nociception (61). Hence, the exact 
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mechanism as to how osteoclasts mediate bone pain is still not clear and warrants further 
investigation.  
2.1.3.2 Bone and joint innervation 
Both Ad and C fibers innervate the bone and different joint compartments, such as ligaments, 
fibrous capsules, synovia and menisci (62). As bones and joints are deep structures, most of 
the innervating sensory nerve fibers are “silent nociceptors” that are only activated by 
inflammation, injury or damage to the surrounding structures. Upon activation, silent 
nociceptors can either be spontaneously active or elicit decreased threshold to mechanical and 
chemical stimulations (63). In stark contrast to the skin, bones and joints are largely innervated 
by thinly myelinated TrkA+ Ad fibers and peptidergic TrkA+ C fibers and, if any, minor 
innervation by non-peptidergic C fibers (64). The reason for this is not yet completely clear.  
Although it appears that the same population of nerve fibers innervate both bones and joints, 
the density, pattern and morphology of innervation are remarkably distinct in these two 
structures. The periosteum, which is a thin layer of connective tissue that covers the outer 
surface of bones except at joint sites, is the most densely innervated compartment. Here, Ad 
and C fibers are organized in a fishnet-like structure, which appears to detect mechanical injury 
and protect the underlying cortical bone (65). The same population of Ad and C fibers also 
innervate the cortical bone and bone marrow, although the relative density of fibers per area is 
considerably lower when compared to the periosteum (63). In a normal joint, the articular 
cartilage lacks any detectable innervation and vascular structures. On the other hand, 
neighboring synovial membrane and subchondral bone are both innervated and vascularized 
(66). Following injury or inflammation, sensory nerve fibers in these compartments may 
undergo sprouting, and thus serve as generator of pain in arthritic conditions (67). Previous 
work also shows that sprouting of TrkA+ sensory nerve fibers in damaged bones are often 
observed with sprouting of TrkA+, tyrosine hydroxylase+ nerve fibers located nearby (68). The 
sympathetic nerve fibers are thought to mediate sensory nerve fiber function and modulate 
hypersensitivity in an experimental model of arthritis (69).  
 
2.1.4 Sex differences in pain 
In the field of pain research, the importance of comparing nociceptive mechanisms in male and 
female subjects has been widely acknowledged. However, before the discovery made by Sorge 
and colleagues that pain in rodents displays sex dimorphism (70), the idea of sex difference in 
pain mechanism was often neglected. Women have long been recognized to outnumber men 
as sufferers of chronic pain (11). Similarly, mounting evidence shows that several animal 
models of pain demonstrate females to be more sensitive to nociceptive stimuli. Among these 
reports, females show earlier emergence of pain in the femoral cancer pain model (71), and 
more allodynia following chronic constriction injury (72) and fracture in the CRPS model (73).  
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Studies on the biological basis of sex dimorphism in pain have been focused on immune system 
differences between male and female subjects. The immune system relies on pattern 
recognition receptors, such as toll like receptors (TLRs), to induce a response. Multiple TLRs 
have been associated with pain, including TLR2 (74), TLR4 (75), TLR5 (76), and TLR7 (77). 
To date, sex dimorphism studies in pain processing have been centered on spinal TLR4. This 
specific interest derived from the finding that two mouse substrains known to have aberrant 
TLR4 functions (C3H/Hej, known to have a point mutation in Tlr4 gene; B10ScNJ, known to 
have recessive null mutation of Tlr4 gene and thus equivalent to Tlr4 knockout mouse) showed 
reduced hypersensitivity in males but not females following nerve injury (70). In support of 
this, intrathecal injection lipopolysaccharide (LPS), which is a TLR4 ligand, evoked 
mechanical hypersensitivity only in male mice. Furthermore, blockade of spinal TLR4 with the 
TLR4 antagonist LPS-RS reversed pain-like behavior in male but not female mice subjected to 
local injections of algogenic agents or nerve injury (70). However, others have shown 
contradicting data with regards to sex-dependent pronociceptive actions of TLR4. For instance, 
activation of spinal TLR4 induced pain-related behavior in both males and females (75, 78), 
although to a greater degree in male mice (78). Administration of TLR4 ligands into the brain, 
hind paw and ankle joint also induced hypersensitivity in both sexes (78). 
As TLR4 is expressed primarily by glial cells in the CNS (32), it is thought that sex-dependent 
responses to TLR4 ligands are differentially regulated at the immune system level. This idea 
prompted researchers to explore if male and female rodents employ different immune cells to 
modulate pain. Indeed, in the CNS, it has been demonstrated that males use microglia, while 
females use the adaptive immune cells, such as T lymphocytes, to regulate hypersensitivity 
(12). In support of this, several studies show that blockade of microglial activity using 
minocycline (a tetracycline antibiotic) led to reversal of pain-associated behavior only in male 
rodents (13, 79, 80). These sex differences are, however, not so clear-cut as microglial 
inhibition has been shown to alleviate pain-related behavior in female rats subjected to bone 
cancer (14). Recently, it was also shown that there is a sex-dependent and temporal contribution 
of microglial TLR4 in nociception in the CRPS model. Microglial TLR4 contributed to 
nociception in the early phase of the model in males, and to a lesser extent in females, while it 
was important for maintenance of hypersensitivity in the late phase in both sexes (81). 
Compared to microglia, there is limited information on astrocytes and sex-dependent 
mechanisms with one only study reporting so far that astroglial signaling is sex-independent in 
both inflammatory and neuropathic pain models (80). Interestingly, reversal of hypersensitivity 
due to common glial inhibitors (e.g. pentoxyfilline, which also inhibits astroglial activity) is 
male-specific in mice (13). In the periphery, reports show that resident immune cells such as 
macrophages play a greater involvement in pain signaling in male rodents compared females 
(82). Thus, more studies are needed to uncover the underlying mechanism of sex differences 
in pain mechanisms.  
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2.2 RHEUMATOID ARTHRITIS  
2.2.1 Pathogenesis of rheumatoid arthritis  
Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease, typically presented 
with symmetrical synovial inflammation, cartilage serration, bone erosion and joint pain 
(arthralgia), which lead to functional impairment and disability. This disease mainly manifests 
into the small joints of the hand and feet, but as the disease advances larger joints such as wrists, 
ankles, knees and hips are afflicted too. RA occurs approximately in 0.5-1% of the global 
population with higher prevalence in women than men (ratio 3:1), and it is predominantly 
observed in the elderly population (5). The etiology of RA remains unclear, although genetic 
and environmental factors have been associated with higher risk of developing RA, such as 
specific human leukocyte antigen (HLA) alleles and cigarette smoking (83). Pain is the 
predominant problem in RA patients and often the main reason for seeking medical help. 
Patients can experience different types of pain with descriptors such as “sharp” and “shooting” 
often used by patients with active disease and “tender” and “gnawing” used by patients with 
low disease activity. Many patients also report neuropathic pain qualities such as “burning” or 
“prickling”, and widespread pain that is usually accompanied with sleep disturbances and low 
mood (6, 84, 85). In addition, arthralgia may prelude signs of inflammation (86, 87), and 
persists even after disease activity is controlled by pharmacological treatments (88, 89). Thus, 
there is poor correlation between inflammation and pain in RA.  
RA is characterized by the presence of autoantibodies in the serum, such as antibodies against 
IgG (rheumatoid factor, RF), anti-citrullinated protein (ACPA), anti-collagen type II (anti-CII), 
anti-carbamylated proteins (anti-CarP) and anti-glucose-6-phosphaste isomerase (anti-GPI). 
Notably, ACPA can be found in approximately 70% of RA patients and frequently used as a 
diagnostic marker. Studies have shown the presence of these autoantibodies up to 10 years 
before the onset of disease (90). Even though there is no detectable inflammation during this 
phase, also known as preclinical phase of RA or “pre-RA”, arthralgia is reported in many 
individuals. The indication of autoantibodies and arthralgia in pre-RA is associated with a 
higher risk for developing RA (91, 92). In addition to this, bone loss is observed at this pre-RA 
stage (93, 94), thus suggesting a potential link between autoantibodies, bone erosion and 
arthralgia. Indeed, prior works have shown that activation of osteoclasts by ACPA leads to the 
secretion of IL-8 and murine homologue chemokine CXC motif ligand (CXCL)1 and CXCL2, 
which may potentially induce nociception by binding to CXC chemokine receptors (CXCRs) 
1 and 2 expressed on sensory neurons (7, 95, 96). This evidence shows an intriguing possibility 
that systemic autoimmunity in RA can mediate arthralgia via effects on bone metabolism 
independent of joint inflammation. Moreover, autoantibodies can form immune complexes and 
directly activate nociceptors by binding to Fc-gamma receptors expressed on neuronal cells 





Figure 1. Autoantibodies mediate nociception via direct/indirect stimulation of nociceptors. In pre-RA, 
autoantibodies (Ab) activate osteoclasts and induce release of IL-8, which may induce nociception by activating 
sensory neurons. Additionally, autoantibodies can form immune complexes (ICs) and can directly activate 
nociceptors by binding to Fc-gamma receptors (FcgR) (right panel). In established RA, pain can be induced by 
activation of different immune cells through release of inflammatory cytokines and pain-inducing factors at the 
inflamed joint site (left panel). Created in Biorender.com. 
 
In addition to the development of RA, autoantibodies are also involved in the active disease 
state. It is thought that an increase in titer, epitope spreading, isotype switching and changes in 
the glycosylation state of autoantibodies results in the pathophysiology of RA (98, 99). 
Autoantibodies bind epitopes in the joint causing an inflammatory cascade via activation and 
infiltration of immune cells, such as monocytes, lymphocytes and fibroblasts. Cytokines 
released by these cells (e.g. TNF, IL-1b, IL-6, IL-15 and IL-17) drive many of the pro-
inflammatory and nociceptive pathways in the synovium (100). RA synovium is also a source 
for essential factors that regulate osteoclast activation and maturation, including RANKL and 
osteoprotegrin ligand derived from either T cells or fibroblasts (101). Consequently, an 
invasive synovial tissue called pannus is formed, which causes further destruction of the 
cartilage, bone and soft tissues of the joints, leading to joint pain and disability (86) (Figure 1, 
left panel).  
As of now, it is still not clear how antibody-induced bone loss, which is present in pre-RA 
conditions, develops into chronic synovitis. One theory suggests that there is diffusion of 
soluble molecules through a communication system between the bone and synovium. 
Furthermore, it has been suggested that bone damage is progressive, initially observed at juxta-
articular sites, but eventually spreading into the cortical bones. During this process, soluble 
molecules in the bones may diffuse along a concentration gradient into the synovium, and 
thereby causing synovial inflammation (86). 
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2.2.2 Pharmacological pain treatment in rheumatoid arthritis 
Current guidelines to treat RA-associated pain include direct acting analgesics and indirect 
acting disease-modifying antirheumatic drugs (DMARDs). Several types of analgesic drugs 
used to treat RA-induced pain include non-steroid anti-inflammatory drugs (NSAIDs), 
paracetamol, opioids, tricyclic antidepressants (TCA) and neuromodulators (e.g. pregabalin, 
gabapentin, capsaicin). TCA and neuromodulators are often used as adjuvant therapies (102). 
However, the efficacy of these pain medications is typically short-term (less than 6 weeks) (6). 
Prolonged use of these drugs is often limited by adverse effect, for example gastrointestinal 
toxicity, renal complications and cardiovascular events with NSAIDs (103). Despite these 
limitations, analgesics provide rapid benefits for RA patients suffering from pain.   
Glucocorticoids and conventional, non-biologic DMARDs such as methotrexate reduce joint 
swelling and inflammation as well as suppress tissue damage within weeks. These may provide 
pain relief up to 12 months with systemic treatment (104, 105). Biologic DMARDs, including 
TNF blockers (etanercept, adalimumab, infliximab), IL-1R antagonist (anakinra) and CD20 
antibody (rituximab), alleviate pain within 2-4 weeks, in conjunction with reductions in joint 
inflammation. Combination therapies, such as methotrexate and glucocorticoids, have been 
shown to provide higher pain reduction (106). In addition, there is a growing popularity of 
combination therapies with methotrexate and biologics, which were shown to be more 
efficacious than methotrexate alone in inhibiting disease progression (107), but there are no 
reports to date showing if these combinations enhance their pain-relieving properties. Still, 
approximately 30% of RA patients continue to suffer from pain, ranging from moderate to 
severe, even though the disease is medically controlled or in remission (108), indicating that 
alternative treatments to anti-inflammatory drugs should be considered for effective pain relief.  
 
2.2.3 JAK/STAT signaling and rheumatoid arthritis  
The Janus kinase/signal transducers and activators of transcription factor (JAK/STAT) is the 
principal signaling mechanism for numerous cytokines and growth factors, many of which are 
involved in the pathogenesis of RA (e.g. IL-6, IL-10, IL-15 and interferons). The JAK family 
consists of 4 tyrosine kinases: JAK1, JAK2, JAK3 and tyrosine kinase (TYK)2, all of which 
function as dimers when phosphorylated by the binding of a specific ligand to its receptor. 
Once phosphorylated, JAKs phosphorylate and activate signaling peptides from the STAT 
family. To date, 7 distinct members of the STAT family have been identified: STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b and STAT6. Upon activation, STAT peptides translocate 
into the nucleus and subsequently initiate gene transcription, which can lead to dysregulation 
of inflammatory and immune responses (109, 110). The broad action of JAK/STAT signaling 
makes it an attractive target for drug development for RA. In fact, three JAK inhibitors are 
clinically licensed by the US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) for treatments of moderate to severe RA: tofacitinib (pan-JAK 
inhibitor with high activity against JAK1 and JAK3), baricitinib (selective JAK1 and JAK2 
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inhibitor) and upadacitinib (selective JAK1 inhibitor) (111). The use of filgotinib, which is 
another selective JAK1 inhibitor, as a treatment of RA has also been recently approved by the 
EMA but it is still yet waiting for approval from the FDA (112). Recently, it was shown that 
tofacitinib and baricitinib can directly affect bone homeostasis and suppress pathological bone 
loss in a mouse model of RA as well as in RA patients by stimulating osteoblast function (113).  
Accumulating clinical data are showing robust pain-relieving effects of tofacitinib and 
baricitinib in RA patients. The efficacy of tofacitinib in improving patient reported outcomes 
(PRO), including pain, has been reported in several phase III clinical trials (ORAL studies). 
These studies reveal that patients with inadequate response to conventional DMARDs report 
significant pain improvements following tofacitinib treatment (114-116). In certain cases, pain 
relief was evident within days of tofacitinib therapy (114). Pain has also been evaluated in the 
recent phase III clinical trial RA-BEAM that compared the effect of baricitinib, adalimumab 
and placebo plus methotrexate. Baricitinib provided greater and faster improvements in terms 
of pain, joint stiffness and fatigue compared to adalimumab (117-119). Intriguingly, the 
antinociceptive actions of baricitinib were not correlated with levels of inflammation in patients 
(119, 120). A more recent clinical study compared the effect of baricitinib, tofacitinib, 
adalimumab and tocilizumab (IL-6 receptor inhibitor) monotherapy on pain in RA patients. 
Baricitinib resulted in greater pain reduction compared to tocilizumab and adalimumab. Of 
interest, no differences in pain improvement were observed between baricitinib and tofacitinib 
treatments (121).  
While clinical evidence clearly demonstrates the pain relieving actions of JAK inhibitors, the 
underlying mechanisms by which these drugs disrupt pain signaling are not fully understood. 
An obvious mechanism is the effect of JAK inhibition on multiples cytokines involved in 
inflammation and pain regulation in RA (122) (Figure 2). This may also explain why JAK 
inhibition leads to greater pain improvements compared to single cytokine inhibitors such as 
adalimumab. Specific cytokines, such as IL-2, IL-6, IL-10, directly activate the JAK/STAT 
pathway. Moreover, even if other cytokines do not signal directly via JAK/STAT, they are 
indirectly affected by its inhibition (e.g. IL-1b and TNF) as production of these cytokines are 
regulated by JAK/STAT activating cytokines. In addition, most of these cytokines are found 
throughout the peripheral and central nervous system, except for a few that are found in specific 
locations. For instance, the action of IL-18 are mostly observed in the periphery close to the 
joint (122). Several studies, however, suggest that the JAK/STAT pathway may be directly 
involved in pain mechanisms. For example, alterations in STAT3 signaling have been reported 
in nerve injury-, chemotherapy- and arthritis-induced pain models (123). In addition to JAKs, 
baricitinib was recently identified as an inhibitor for the adaptor protein-2 (AP-2) associated 
kinase 1 (AAK1), which is an important regulator of clathrin-mediated endocytosis. This 
discovery has been monumental for the current COVID-19 pandemic as AAK1 serves pivotal 
role for viral entry, and therefore baricitinib can be used as an alternative COVID-19 therapy 
(123). The binding affinity to AAK1 is exclusive for baricitinib and was not observed in other 
JAK inhibitors, such as tofacitinib and upadacitinib (124). Interestingly, AAK1 blockade also 
leads to alleviation of pain-like behavior in neuropathic pain models suggesting a role of AAK1 
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Figure 2. The involvement of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway in cytokine signaling that drives central and peripheral mechanisms of pain in rheumatoid arthritis. 
Certain cytokines such as IL-6 and IL-15 signal directly through the JAK/STAT pathway, however other cytokines 
such as IL-1b and TNF do not directly activate JAK/STAT signaling but may be indirectly affected by JAK 
inhibitors. Created with Biorender.com. 
 
2.2.4 Rheumatoid arthritis-induced pain models 
Over the years, studies using preclinical models have provided important information about the 
pathology that drives and maintains pain in RA. Surprisingly, there has been minimal overlap 
between the animal models used in RA and pain fields. This is because models of monoarthritis 
induced by injections of either complete Freund’s adjuvant (CFA) (126) or carrageenan into 
the paw or joint are more frequently used to study pain. Although these models develop robust 
inflammation and pain-related behaviors, they do not recapitulate the complexity of RA as they 
are relatively short lasting and largely dependent on only the innate immune system. Besides, 
these models are not suitable to conduct studies on the uncoupling between inflammation and 
pain. At present, there has been a growing number of more disease-relevant RA models used 
for pain studies, including the collagen-induced arthritis (CIA) (127), antigen-induced arthritis 
(AIA) (128), collagen antibody-induced arthritis (CAIA) (129, 130) and K/BxN serum transfer 
models (131-133). These preclinical models have enabled researchers to dissect the 
multifactorial nature of pain pre-, during, and post-inflammation. Furthermore, transfer of RA 
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patient-derived autoantibodies such as ACPA into naïve mice produces long-term behavioral 
nociception and bone erosion despite not generating visual or histological signs of 
inflammation (7, 96). Although not yet an established RA model, this model is useful to study 
“pre-RA” arthralgia and decipher the missing link between inflammation and pain. 
This thesis work is focused on studying pain in the CAIA model, which is induced by 
intravenous (i.v.) or intraperitoneal (i.p.) injection of a mixture of CII antibodies (IgG2a and 
IgG2b) followed by i.p injection of LPS. Consequently, this induces transient polyarthritis that 
lasts around 3-4 weeks as the antibodies are cleared (129, 130). The occurrence of transient 
inflammation provides a good opportunity to study pain in different phases of RA flares. 
Indeed, mechanical hypersensitivity has been reported pre-, during and post-inflammation in 
this model (75, 97, 134, 135). In addition, mice exhibit thermal hypersensitivity (134, 136) and 
reduced locomotor activity (137). Another clinically relevant feature of this model is that 
female mice are more susceptible in developing joint inflammation compared to male mice 
(13), thus representative of the fact that RA is more prevalent in women than men. Although 
the CAIA model has now been utilized for several pain-related studies, there are certain aspects 
of this model that remain to be elucidated. For instance, damages to the bone remain several 
weeks after resolution of inflammation (134), and this raises the question whether changes in 
the bone environment mediate persistent pain in RA.  
 
2.3 HIGH MOBILITY GROUP BOX 1 
Alarmins or damage-associated molecular pattern molecules (DAMPs) are endogenous 
molecules that form an important component of the innate immune system as their release 
serves as a signal for cell or tissue damage. High mobility group box 1 (HMGB1) protein, 
previously known as amphoterin or HMG-1, is a chromatin-binding protein that modulates key 
DNA events inside the nucleus, but also operates as a critical DAMP upon tissue injury or 
inflammation. Excessive amount of extracellular HMGB1 is implicated in the pathogenesis of 
various inflammatory and autoimmune diseases, including RA, and it is now recognized that 
HMGB1 also plays important roles in nociceptive signaling (138). Given such diverse roles, 
HMGB1 represents an interesting molecule to study in the context of RA and pain.  
 
2.3.1 HMGB1: characteristics and functions  
HMGB1 is a ~ 25-kDa protein of 214 amino acids that consists of two positively charged DNA 
binding motifs (A box and B box) and a negatively charged acidic C terminal. This protein also 
contain two nuclear localization signal (NLS), NLS1 and NLS2, for controlled nuclear 
transport (139). The amino acid sequence is highly conserved, with over 98% homology 
between humans and rodents. Studies have shown that the activities of secreted HMGB1 are 
largely dependent on the redox state of three cysteines at amino acid positions 23, 45 and 106 
(140) (Figure 3). Reduction of these three cysteines results in fully reduced or all-thiol HMGB1 
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that acts as a ligand for receptor for advanced glycation products (RAGE) and promotes 
chemotactic activity via CXCR4 by forming a heterocomplex with CXCL12 (140). Nuclear 
and cytoplasmic HMGB1 is thought to exist in all-thiol form and most likely also initially upon 
release. As the extracellular environment is more oxidizing than the intracellular compartment, 
HMGB1 can undergo redox modifications after being released. If the cysteine thiol groups at 
positions 23 and 45 are oxidized, leaving the cysteine at position 106 in its thiol form, a 
disulfide bridge between C23 and C45 is formed. This modification converts HMGB1 into the 
disulfide form that induces nuclear factor-kappa B (NF-kB) activation and cytokine production 
by binding to TLR4 through its extracellular adaptor, myeloid differentiation factor-2 (MD-2) 
(141). Oxidation of the three cysteines leads to formation of fully oxidized HMGB1, which is 
considered to be the inactive form of HMGB1 as it has not been associated with a pro-
immunogenic function (142). The conversion between all-thiol and disulfide redox forms is 
reversible, whereas modification into the fully oxidized isoform is irreversible (143). 
 
 
Figure 3. The structure and redox regulation of HMGB1 activity. The redox state of three cysteines located at 
amino acid 23, 45 and 106 within the protein regulates which receptor HMGB1 binds to and the functional 
consequence of its release. Created with Biorender.com.  
 
HMGB1 release into the extracellular space involves passive and active cellular mechanisms. 
Passive release of HMGB1 is caused by necrotic cell death and the process is spontaneous. On 
the other hand, active HMGB1 secretion takes place as a result of tissue injury or inflammation, 
and is a relatively slower process than passive discharge. This process involves membrane 
receptor activation, such as binding of pathogen-associated molecular patterns (PAMPs; e.g. 
LPS, IL-1 and TNF) to their corresponding receptors, and activation of intracellular signal 
transduction (144-146). In general, active release of HMGB1 requires two crucial steps. The 
first step is the initial nucleus to cytosol shuttling of HMGB1 that involves JAK/STAT1-
mediated acetylation of lysine residues located in NLS1 and NLS2 that prevents HMGB1 
transport back to the nucleus (139, 145). The second step is the extracellular release of HMGB1 
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that could either involve inflammasome-controlled pyrotopsis or vesicle-mediated secretory 
pathway (147, 148).  
Once released extracellularly, HMGB1 regulates various immunological functions such as 
activation of immune cells, production of cytokines, chemotaxis, and cell proliferation and 
differentiation. The broad repertoire of HMGB1’s actions is mediated by the fact that this 
protein can interact with different receptor systems. As of now, at least 14 receptors have been 
reported to be targets for extracellular HMGB1 (149). In addition to TLR4 and RAGE that are 
mentioned above, HMGB1 has been reported to act as a ligand for other TLRs such as TLR2 
and TLR5, although the precise molecular interactions between HMGB1 and these receptors 
are still unknown (76, 150). HMGB1 can also activate other receptor systems such as IL-1R, 
CD24 and Siglec-10 (Siglec-G in mice). However, these receptors are most likely receptors for 
molecules that can form complexes with HMGB1 (e.g. LPS, IL-1b, viral RNA, nucleosomes). 
Thus so far, direct interactions of HMGB1 with receptors are only clarified for TLR4 and 
RAGE. Nevertheless, the ability of HMGB1 to form complexes is an important mechanism for 
HMGB1-mediated inflammation since this elevates the responses as compared to induction by 
the ligand alone (151, 152).  
Knowledge on HMGB1 and its receptor interactions originated from preclinical studies that 
primarily used male subjects, however increasing data show that similar HMGB1 activities are 
detected in females (Table 2). In preclinical studies, disulfide HMGB1 has been shown to 
induce muscle fatigue in both male and female mice, which is dependent on TLR4 but not 
RAGE signaling (153). HMGB1 signaling via RAGE and TLR2 has also been reported in 
several experimental models associated with cancer (154), lupus (155) and heart disorders 
(156) in female mice. There is also a growing number of preclinical pain studies that 
demonstrate these types of interactions in both male and female mice, and this will be further 
discussed in part 2.3.3. In clinical studies, HMGB1-TLR4 interactions are strongly implied in 
men and women infected with HIV (157), and in women with ovarian cancer (158). 
 





Pathological conditions Species Sex/gender Refer- 
ences 
Disulfide TLR4 Myositis Mouse Male, female (153) 
Disulfide TLR4 Osteoarthritis Mouse Female (159) 
- RAGE Myocarditis Mouse Female (156) 
- TLR2 Brain cancer Mouse Female (154) 
- TLR2 Lupus nephritis Mouse Female (155) 
- TLR4/MD-2 HIV infection Human Male, female (157) 
- TLR4 Ovarian cancer Human Female (158) 
 
To maintain homeostasis, pro-inflammatory factors, including HMGB1, are subject to 
downregulation. Several endogenous molecules have been identified to sequester and 
neutralize HMGB1. Haptoglobin, a protein that binds free hemoglobin, is an example of such 
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factors that can dampen pro-inflammatory activity of HMGB1. This protein forms a complex 
with either all-thiol or disulfide HMGB1, which are then taken up by macrophages via the 
scavenger receptor CD163 and this results in the release of anti-inflammatory mediators, such 
as heme oxygenase-1 and IL-10 (160). Another example is the endothelial thrombin-binding 
protein thrombomodulin that can interact with HMGB1 and promotes proteolytic cleavage by 
thrombin (161). The complement protein C1q can also interact with HMGB1 and shifts 
macrophage polarization into anti-inflammatory M2-like macrophages (162). Furthermore, the 
HMGB1 receptor RAGE exists in a soluble form (sRAGE) and can act as a decoy receptor that 
neutralizes the pro-inflammatory actions of  HMGB1 (163).  
 
2.3.2 HMGB1 and rheumatoid arthritis 
Accumulating evidence shows a strong connection between HMGB1 and RA, with several 
studies suggesting that HMGB1 is released at the site of joint inflammation. Indeed, enhanced 
levels of extranuclear HMGB1 are detected in synovial fluid and synovial biopsies from RA 
patients (164-166). HMGB1 levels in RA synovial fluid are markedly higher when compared 
with samples derived from osteoarthritis patients (166). In addition, HMGB1 expression in 
inflamed synovium is predominantly observed in macrophages and vascular endothelial cells 
(166). HMGB1 levels are also increased in sera of RA patients and this correlates with higher 
disease activity (167).  
Important discoveries regarding the role of HMGB1 in RA also comes from animal studies. In 
synovial tissues of the CIA model, HMGB1 expression was increased in the extracellular space 
and cytoplasm of macrophages, fibroblasts and endothelial cells, while it was restricted to the 
nucleus in healthy animals (165, 168). HMGB1, in synergy with vascular endothelial growth 
factor (VEGF), also induced neovascularization in the synovium and contributed to pannus 
formation in the CAIA model (169). Moreover, animal studies have shown the important 
contribution of HMGB1 in osteoclastogenesis (170, 171), and thus may suggest a role of 
HMGB1 in RA-associated bone loss. Another key observation pointing to the role of HMGB1 
in RA is that injection of recombinant HMGB1 into murine knee joints triggered long-term 
arthritic symptoms (172). Consistently, inhibition of HMGB1 with specific antagonists reduced 
clinical signs of arthritis and conferred significant protection against structural damage to the 
joint in several experimental models of RA (173-176). Of relevance to the antagonist used in 
this thesis work, the monoclonal HMGB1 antibody (2G7) alleviated joint inflammation, but 
only partially prevented cartilage and bone destruction in two arthritis model: CIA and a 
spontaneous RA model induced by deficiencies in genes encoding enzyme DNase type II and 
interferon type I receptor (177). To date, there is no anti-HMGB1 therapy approved for clinical 
use, but animal studies show potential benefits of targeting HMGB1 in RA. Currently, two 
different humanized anti-HMGB1 monoclonal antibodies have been identified (149), but 




2.3.3 HMGB1 and pain 
It is now established that HMGB1 mediates the molecular pathways that drive and maintain 
nociception with mounting evidence showing that local administration of HMGB1 cause pain-
like behavior in rodents. The earliest indication of this observation was reported 20 years ago 
whereby HMGB1 delivery onto rat sciatic nerve via a preimplanted indwelling perisciatic 
catheter was shown to evoke hypersensitivity to mechanical stimulation in a dose-dependent 
fashion (178). Similar observation was reported following the delivery of HMGB1 into sciatic 
nerves exposed by blunt dissection (179). Subsequently, it was shown that intrathecal injection 
of HMGB1 in naïve rats promoted lower threshold responses to calibrated touch/pressure 
stimuli (180). In mice, intrathecal injection of HMGB1 induced similar behavioral outcomes 
that last up to 5 days post-injection (75). Collectively, these studies establish the peripheral and 
central actions of HMGB1 in nociceptive signaling.  
Since the discovery of the different HMGB1 isoforms and the importance of this structural 
change for HMGB1 functions, emerging evidence shows that the pronociceptive role of 
HMGB1 is also redox-dependent. In addition to this, the pronociceptive actions of HMGB1 
and its interplay with different receptors may differ between sites (Table 3). Studies show that 
robust pain-like responses were elicited in mice following injection of disulfide, but not all-
thiol, HMGB1 into the ankle joint (138), bladder (181, 182), spinal cord (75) or brain (183), 
via TLR4 signaling. Both isoforms of HMGB1 were, however, pronociceptive when injected 
intraplantarly. However, it should be taken into account that a 10-fold higher dose of all-thiol 
HMGB1 in comparison to disulfide HMGB1 was needed to produce this effect (184). 
Interestingly, it was shown that both HMGB1 isoforms promoted excitation of primary DRG 
neurons, but a slightly higher percentage of cells responded to stimulation with all-thiol 
compared to disulfide HMGB1 (185). 
 
Table 3. Pain-inducing effects of different HMGB1 isoforms administered via several routes in rodents  
Route of 
administration 
HMGB1 isoform Target receptors Pain assessment References 
Intraplantar Disulfide, all- thiol TLR4, RAGE Mechanical  (184) 
Intra-articular Disulfide TLR4 Mechanical  (138) 
Intravesical Disulfide TLR4 Mechanical  (181, 182) 
Intrathecal Disulfide TLR4 Mechanical  (75) 
Intracisternal Disulfide TLR4 Mechanical, thermal  (183) 
 
Other key observations that indicate important roles of HMGB1 in nociception include elevated 
levels of extranuclear HMGB1 found in the DRGs, spinal cords and sciatic nerves in models 
of neuropathic and RA-induced pain. These changes often occur in concomitance with pain-
associated behavior in the animals (75, 179, 186, 187). As the presence of extranuclear 
HMGB1 indicates translocation out of the nucleus and may be interpreted as release, 
extracellular HMGB1 in the nervous system can thus originate from neurons, glial cells and 
immune cells. Multiple TLRs and RAGE are expressed by these cells (188), and therefore 
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HMGB1 could directly affects nociceptor activity as well as induce an indirect effect by 
promoting the release of algesic factors from cells in the proximity.  
Mounting data further supporting the role of HMGB1 in pain mechanisms show that blockade 
of endogenous HMGB1 led to attenuation of nociceptive in several experimental models. 
Global HMGB1 knockout mice has not been possible to use as this genetic depletion is lethal 
in newborn mice (189), and there are no reports of the use of conditional HMGB1 knockout 
for pain studies. Instead, several pharmacological agents that suppress HMGB1 activity have 
been used (Table 4). The reversal effects of neutralizing HMGB1 antibodies have been shown 
in numerous models of pain including those subjected to nerve injury (179, 187, 190) or 
arthritis (75). The truncated HMGB1 A Box domain, which inhibits HMGB1 activity in a yet 
unresolved mode of action, has also been reported to be antinociceptive in the CAIA model 
(75). Moreover, the antinociceptive effects of glycyrrhizin, a natural triterpene glycoside that 
has anti-inflammatory and antiviral properties, and thrombin-binding TM have been 
demonstrated in various pain models such as models of visceral pain (191-195). Together, this 
points to the potential use of HMGB1 blocking agents to treat different painful conditions.  
 
Table 4. The antinociceptive effects of HMGB1 antagonists in experimental models of pain 
HMGB1 
antagonist 
Pain model Route of 
administration 
Pain assessment References 
HMGB1 Ab Nerve injury Perisciatic, 
i.p., i.t. 
Mechanical, thermal (179, 187, 
190) 
      CIPN i.p. Mechanical, paw pressure, thermal (196, 197) 
 Diabetic neuropathy i.t. Mechanical (198) 
     Arthritis/joint pain i.pl., s.c., i.t. Mechanical, paw pressure, thermal (75, 199) 
 Visceral pain i.p., i.t. Mechanical, licking/biting lower 
abdomen 
(193-195) 
     CIBP i.p., i.t. Mechanical (200-202) 
      Orofacial pain i.p., i.t. Mechanical, thermal (183) 
Box-A peptide Arthritis/joint pain i.t. Mechanical  (75) 
Glycyrrhizin Nerve injury i.p. Mechanical  (186) 
 Diabetic neuropathy i.p. Paw pressure, thermal (203) 
     Arthritis/joint pain i.p. Mechanical, thermal (204) 
 Visceral pain i.p., i.t. Mechanical (191, 192) 
TM CIPN i.p.  Mechanical, paw pressure, thermal (196, 197) 
      Visceral pain  i.p. Mechanical, licking/biting lower 
abdomen 
(193-195) 
CIPN: chemotherapy-induced painful neuropathy; CIBP: cancer-induced bone pain 
 
Given that TLR4 is a receptor of HMGB1, one may assume that there is a general interest in 
examining if the role of HMGB1 in nociception is sex-dependent. Surprisingly, there is a 
limited number of studies that perform direct comparisons between males and females when it 
comes to examining the nociceptive roles of HMGB1 in RA. It has been shown that spinal 
delivery of disulfide HMGB1 lowers mechanical withdrawal thresholds in both male and 
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female mice, and that blocking the action of spinal HMGB1 provides pain-relieving effects in 
the CAIA model in both sexes (75). Even though it has been shown that HMGB1 evokes pain-
like responses when administered into the ankle joint (138), the sex-dependent role of HMGB1 
in the periphery was not explored. Previous work also shows that spinal glial inhibition led to 
reversal of mechanical hypersensitivity in male but not female mice subjected to late phase 
CAIA (13). However, it is not known if the observed sex differences are attributed to HMGB1. 
Though it has been reported that intrathecal injection of HMGB1 induced microglial activation 
in the spinal cord (75), this observation has not been linked to sex differences. Further studies 




Treatment for RA has changed profoundly over the past decade but despite adequate disease 
improvements with current antirheumatic drugs, pain is still a significant problem for patients. 
Patients with RA are found to have persistent pain despite well-controlled inflammation. A 
growing body of evidence suggests that that specific components of pain in RA are not coupled 
to inflammation and that patients may benefit from alternative therapies to anti-inflammatory 
drugs. One could argue that a possible strategy to circumvent this is to target the bone 
microenvironment since RA-affected joints exhibit increased bone erosion. However, it is still 
not known how cells in the bone mediate pain in RA and if inhibitors that could alter bone 
metabolism (e.g. bisphosphonates) may provide beneficial effects on pain. RA is also known 
as a complex disease involving different inflammatory factors, many of which have been 
suggested to cause a chronic neuroinflammatory state that may maintain pain in patients. 
Accumulating evidence shows that this condition may be mediated by the JAK/STAT signaling 
pathway or the DAMP molecule HMGB1. HMGB1 being an endogenous ligand of TLR4 is 
also an interesting molecule to explore with regards to sex differences in pain mechanism. 
Taken together, unraveling these alternative mechanisms may open new perspectives on novel 






3 RESEARCH AIMS 
 
This thesis has the overall aim to explore novel mechanisms that drive persistent pain in 
rheumatoid arthritis, focusing on the role of the bone environment and neuroinflammatory 
factors, and if specific mechanisms are sex-dependent. Thus, this thesis has three specific aims: 
1. To elucidate the mechanisms by which osteoclasts mediate long-lasting 
hypersensitivity in the collagen antibody-induced arthritis model 
 
2. To identify the effect of the JAK/STAT inhibitor baricitinib on pain-related behavior 
and its antinociceptive mechanism in the collagen antibody-induced arthritis model 
 
3. To understand the role of peripheral and central HMGB1 in arthritis-induced pain and 








4 MATERIALS AND METHODS 
 
4.1 ANIMAL STUDIES 
4.1.1 Animals  
All animal works were approved by the local ethical committees for animal experiments in 
Sweden (Stockholm Norra djurförsöksetiska nämnd), France (Comité Régional d’Éthique en 
Matière d’Expérimentation Animale Auvergne) and USA (Institutional Animal Care and Use 
Committee of The University of Texas at Dallas). This thesis works also conforms to the 
Animal Research: Reporting of In Vivo Experiments (ARRIVE) and IASP guidelines. Animals 
were housed in standard cages (4-5 mice/cage) in a temperature-controlled environment with 
12 h light/dark cycle and access to food and water ad libitum.  
Different mouse strains and genetically modified mice were used across different studies. For 
Paper I and II, BALB/c female mice were obtained from Janvier Laboratories. For Paper III, 
BALB/c and C57BL/6 male and female were purchased from Janvier Laboratories and Charles 
River. In addition, male and female mice with specific TLR4 deletion in myeloid cells or 
nociceptors were used in this study. To generate cell-specific TLR4 depletion, TLRfl/fl mice 
were used as previously described (205). TLR4fl/fl mice were then crossed with mice expressing 
Cre under the control of the Lysozyme M (LysM) or Nav1.8 promoters to breed mice having 
TLR4 deletion in myeloid cells peripheral or nociceptors, respectively. The resulting LysM-
TLR4fl/fl, Nav1.8-TLR4fl/fl, and TLR4fl/fl (control mice) were backcrossed and bred for 8 
generations to a C57BL/6 background at the University of Texas at Dallas. Paper IV used 
C57BL/6 male and female mice, purchased from Janvier Laboratories, as well as the two cell-
specific TLR4 depleted mice (LysM-TLR4fl/fl and Nav1.8-TLR4fl/fl) described above. 
Proteinase-activated receptor (PAR)2-deficient (PAR2-/-) mice obtained from Jackson 
Laboratory and bred at the University of Texas at Dallas were also used in Paper IV.  
 
4.1.2 Animal models 
4.1.2.1 Collagen antibody-induced arthritis model 
For Paper I-III, the CAIA model was achieved as previously described (134). BALB/c male 
and female mice were injected i.v. with anti-collagen type II (CII) arthritogenic antibody 
cocktail (1.25-1.5 mg/mouse, purchased from Chondrex) on day 0 followed by i.p. injection of 
LPS (5-25 µg/mouse) on day 3 or 5 to boost and synchronize joint inflammation. A control 
group receiving saline solution i.v. on day 0 and i.p. on day 3 or 5 was included in all studies.  
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The degree of inflammation was assessed by visual inspection of the fore and hind paws. A 
score of 1 point was given for each inflamed toe or knuckle and a score of 2.5 or 5 points was 
given for each inflamed wrist or ankle for either moderate or severe inflammation. This results 
in maximum possible scores of 15 points per paw and 60 points per mouse. Incidence of 
arthritis refers to the percentage of animals that developed signs of joint inflammation. BALB/c 
female mice developed higher arthritis incidence than BALB/c male mice, as also reported 
previously (13). For Paper I-III, CAIA mice that did not receive any drug treatments were 
excluded from the study if they did not reach a score of 12 points. 
4.1.2.2 Complete Freund’s adjuvant-induced monoarthritis  
For Paper II, monoarthritis was evoked in mice by unilateral intra-articular injection of 
complete Freund’s adjuvant (CFA, 10 mg/mL) into the ankle joint in 2.5 μL volume, which is 
equivalent to 10 μg CFA per mouse. The procedure was performed under isoflurane anesthesia.  
4.1.2.3 Spared nerve injury model 
For Paper II, the spared nerve injury (SNI) model of neuropathic pain was performed on mice 
as previously described (206). Briefly, SNI was achieved by ligation (with 6-0-silk suture) and 
transection of tibial and common peroneal nerves under isoflurane anesthesia leaving the sural 
nerve intact. Control mice were sham-operated by exposing the sciatic nerves, without 
performing nerve ligation and transection. Subsequent to surgery, mice received subcutaneous 
(s.c.) injection of buprenorphine (0.1 mg/kg) every 12 h for 48 h. 
 
4.1.3 Drugs and drug delivery 
Different categories of drugs/reagents, including osteoclast and HMGB1 inhibitors, were used 
across Paper I-IV. All drugs, with their route of administration and doses, used for 
pharmacological experiments are summarized in Table 5.  
4.1.3.1 Osteoclast inhibitor 
For Paper I, two different osteoclast inhibitors were tested, the bisphosphonate zoledronate 
and the cathepsin K inhibitor tanshinone IIA sulfonic sodium (T06). Zoledronate is a third 
generation, nitrogen containing bisphosphonate that is used to treat and prevent osteoporosis, 
bone complications due to cancer, osteogenesis imperfecta and Paget’s disease (207). As other 
bisphosphonates, zoledronate preferentially binds to calcium ions and accumulates in the bone. 
During the process of bone degradation mediated by osteoclast, zoledronate can enter 
osteoclasts and affects their differentiation, cell survival and cytoskeletal dynamics. On the 
other hand, T06 is a derivative of Tanshinone IIA, a natural component of the herb Salvia 
miltiorrhiza, which is used in traditional Chinese medicine for cardiovascular disorders. It 
binds to an ectosteric site of cathepsin K remote from its active site and subsequently suppresses 
the ability of osteoclasts to degrade collagen (208). For Paper I, zoledronate (100 µg/kg) was 
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injected subcutaneously (s.c.) every 3 days and phosphate-buffered saline (PBS) was used as 
vehicle control. T06 (40 mg/kg, q.d.), which was kindly provided by Dr. Dieter Brömme 
(University of British Columbia, Vancouver, Canada), was administered per oral gavage and 
distilled water was used as vehicle control.   
 
Table 5. List of drugs/reagents used in animal studies 
Drug/reagents Category Paper Route Dose Dosing regimen 
2G7 Anti-HMGB1 mAb III s.c. 100 µg/mouse q.d. 
Alpha-1-antitrypsin Protease inhibitor IV i.t. 15-30 ng/mouse once/twice inj. 
All-thiol HMGB1 Recombinant protein III-IV i.a. 1 µg/mouse once inj.  
Baricitinib JAK inhibitor II p.o. 20-40 mg/kg q.d. or b.i.d 
Disulfide HMGB1 Recombinant protein III-IV i.a. or i.t. 1 µg/mouse once inj. 
Haptoglobin HMGB1 sequester IV i.t. 15 µg/mouse once inj. 
Minocycline Macrophage/microglia 
inhibitor 
III-IV i.a. or i.t. 30-100 
µg/mouse 
once/twice inj. 
NP137 Anti-netrin-1 Ab I i.p. 10 mg/kg 3 times/week 
Sivelestat Elastase inhibitor IV i.t. 0.5-1 ng/mouse once/twice inj. 
T06 CatK inhibitor I p.o. 40 mg/kg q.d. 
Zoledronate Bisphosphonate I s.c. 100 µg/kg every 3 days 
mAb: monoclonal antibody; q.d.: once daily; b.i.d.: twice daily; inj.: injection 
 
4.1.3.2 Netrin-1 inhibitor 
The humanized monoclonal antibody of IgG1 isotype targeting netrin-1 (NP137) developed by 
Netris Pharma (Lyon, France) (209) was used in Paper I to inhibit netrin-1 signaling. NP137 
(10 mg/kg) was administered via i.p. injection three times a week. For vehicle control, a control 
buffer (containing 20 mM Tris, 5% sucrose and 0.01% Tween 20) was used.  
4.1.3.3 JAK inhibitor  
Baricitinib is a selective JAK1/2 inhibitor, which has been approved by both FDA and EMA 
for treatment of RA (111). For Paper II, baricitinib was kindly provided by Eli Lilly 
(Indianapolis, IN, USA). Baricitinib (20-40 mg/kg, q.d. or b.i.d) was administered per oral 
gavage and for vehicle control, 0.5% methylcellulose was used.  
4.1.3.4 HMGB1 inhibitor  
The anti-HMGB1 non-commercial monoclonal antibody (2G7) was produced in house (210), 
and used in Paper III to suppress the activity of endogenous peripheral HMGB1. This antibody 
binds to an epitope within the amino acid region at position 53 to 65 of the A box unit. 2G7 
(100 µg/mouse, q.d.) was administered via s.c. injection and PBS was used as vehicle.  
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4.1.3.5 Microglia/macrophage inhibitor 
Minocycline is a tetracycline antibiotic used to treat various bacterial infections, which has also 
previously been used in preclinical studies as microglia/glia inhibitor (13). For Paper IV, mice 
received intrathecal (i.t.) injection minocycline (30 µg/mouse), whereas control mice received 
intrathecal injection of saline, all in 5 μL volume. As minocycline also exhibits inhibitory 
effects on macrophages (211), it was also used as a macrophage inhibitor for Paper III. Mice 
were given intra-articular (i.a.) injection of minocycline (30-100 µg/mouse), while control mice 
received i.a. injection of saline, all in 2.5 μL volume.  
4.1.3.6 HMGB1 (different redox forms) 
Different redox forms of HMGB1 were used in Paper III and IV; all-thiol HMGB1 (RAGE 
ligand, chemoattractant form) and disulfide HMGB1 (TLR4 ligand, cytokine-inducing form) 
(75). Both isoforms of HMGB1 were kindly provided by Dr. Huan Yang (Feinstein Institute 
for Medical Research, Manhasset, NY, USA) or purchased from HMGBiotech (Milan, Italy). 
In Paper III, i.a. injection of both all-thiol and disulfide HMGB1 (1 µg/mouse) was performed 
to investigate the redox-dependent nociceptive effects of peripheral HMGB1. For Paper IV, 
only disulfide HMGB1 (1 µg/mouse) was used for i.t. injection. For all studies, either i.a. or i.t. 
injection of PBS was used as vehicle control.  
4.1.3.7 Alpha-1-antitrypsin 
Alpha-1-antitrypsin (A1AT) is an inhibitor of serine proteases, primarily elastase but also other 
proteases such as proteinase 3 and cathepsin G (212). A1AT (15-30 ng/mouse) was either co-
injected with disulfide HMGB1 or injected alone into the spinal cord in Paper IV.   
4.1.3.8 Haptoglobin 
Haptoglobin is a protein produced by the liver that clears free hemoglobin, which can induce 
deleterious oxidative activity. It has been shown that haptoglobin sequesters HMGB1 via 
CD163 and this elicits release of anti-inflammatory factors (160). In Paper IV, haptoglobin 
(15 µg/mouse) was injected i.t. in combination with disulfide HMGB1.   
4.1.3.9 Sivelestat 
Sivelestat is a selective leukocyte elastase inhibitor (213). Sivelestat (0.5-1 ng/mouse) was 
either co-injected with disulfide HMGB1 or injected alone into the spinal cord in Study IV.   
 
4.1.4 Assessment of pain-like behavior 
In Paper I-IV, mechanical hypersensitivity was examined as a measure of evoked pain-like 
behavior. Mechanical hypersensivity in the hind paws was assessed by von Frey OptiHair 
filaments (Marstock). Briefly, animals were habituated to the testing environment, which are 
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single units on an elevated mesh platform, before baseline measurements (3-5 measurements) 
and randomization into experimental groups. On indicated test days, animals were acclimatized 
to the testing apparatus for 30-45 prior to measurements. A series of filaments with a 
logarithmically incremental stiffness of 0.5, 1, 2, 4, 8, 16 and 32 mN (corresponding to 0.051 
g, 0.102 g, 0.204 g, 0.408 g, 0.815 g, 1.63 g, and 3.26 g, respectively) were applied to the 
plantar surface of the hind paw and held for 2-3 seconds. A cut-off of 4 g was applied to avoid 
tissue damage. A brisk withdrawal of the paw was noted as a positive response. Values were 
calculated as 50% withdrawal thresholds (i.e. the thresholds of mechanical hypersensitivity at 
which there was a 50% probability of paw withdrawal) using the Dixon up-down method (214). 
Withdrawal thresholds from both hind paws were averaged, except in unilateral experiment 
such as i.a. injection of HMGB1 where only the ipsilateral paw was considered for analysis. 
Data are presented in grams or as percentage change to the mean baseline values within each 
treatment groups. However, when there was a great variation of baselines between groups, 
withdrawal thresholds are presented as percentage change to individual baseline values. For 
certain experiments, mechanical hypersensitivity was presented as a hyperalgesic index (HI 
index), which is calculated from the area between the extrapolated baseline and the time-
response curve following nociceptive procedure (i.e. HMGB1 i.a. injection), or calculated as 
area under the curve (AUC) during specific treatment periods (i.e. baricitinib treatment). 
Increasing HI index indicates increasing hypersensitivity, while it is the opposite for AUC 
assessment. All behavioral experiments were performed in a blinded fashion throughout the 
experiment and data analysis to avoid bias. 
 
4.1.5 Ethical considerations 
Throughout this thesis work, strict policies were followed when it comes to the welfare and 
well-being of the animals. All procedures conformed to the regulations of the approved ethical 
permits as well as the ARRIVE and IASP guidelines stated above. Apart from this, the Russell 
and Burch 3R’s principle (Replacement, Reduction and Refinement) of human experimental 
techniques were carefully implemented.   
One would argue if there are ethical debates about using animals, one should turn to alternatives 
(Replacement). Although a great amount of work has been done in our laboratory, we were 
unsuccessful in identifying cell lines that would mimic their physiological properties in vivo, 
and this why primary cell cultures are still used for this thesis work. Human patients and 
cadaveric samples have also been used in the past to replace animal studies as well as 
sidestepping the issue of translation between species, however the data generated are often 
needing to be complemented by animal studies and thus animal research cannot be completely 
eliminated. 
Careful decision is ensured on how many animals are included for each experiments 
(Reduction). No statistical tests were used to predetermine sample size. Instead, the general 
consensus implemented here is that no more than 10 mice per group are included, but if this 
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number does not give a statistically significant outcome, more mice included would be 
justifiable to detect small changes and give us more information. It should also be considered 
if reducing the number of animals would lead to heavier burden on those animals included in 
the study. For instance, repeated behavioral experiments or injections/surgical intervention in 
one animal as compared to spreading these procedures on several animals. The issue about 
animal numbers has become more of a problem since the discovery that there are sex 
differences in pain mechanisms. Traditionally researchers tend to use either males or females 
for practicality and by including both sexes the number of subjects would double substantially. 
One of the aims of this thesis is to understand if the regulation of pain processing is sex-
dependent and therefore this factor is unavoidable for this work. 
In terms of animal welfare, a close contact with veterinarians and animal technicians was 
maintained before the experiment as evident by project plans being made as well as throughout 
the course of experiment (Refinement). When inducing a severe model for example the CAIA 
model, it is the responsibility of the researcher to take daily care of the animals as well as to 
communicate with the animal technicians all of their needs and to take immediate actions if 
humane endpoints are reached. Enriched and stable environment was carefully monitored to 
reduce stress for animals. Furthermore, refinement was also applied for the experiment 
protocols themselves, as such that the intensity and duration of pain are minimized. In the 
classical von Frey test in which filaments with incremental force are applied on the plantar side 
of the paw, the experimenter decides the maximum force that could be applied based on the 
animal’s withdrawal response in order to prevent intensified pain and injury.  
 
4.2 CELL CULTURE  
4.2.1 Osteoclast culture  
In Paper I, primary osteoclast cultures were generated from mouse tibial and femoral bone 
marrow. Cells were isolated by centrifugation at 300g for 5 min and resuspended in Eagle’s 
Minimum Essential Medium - alpha modification (aMEM) supplemented with 10% fetal 
bovine serum (FBS), 50 U/mL penicillin, 50 µg/mL streptomycin, 30 ng/mL macrophage 
colony-stimulating factor (M-CSF) and 50 ng/mL receptor activator of nuclear-kappa B ligand 
(RANKL). Cells were then seeded onto appropriate culture plates at a density of 1.25 x 105 
cells/well and cultured for 6 days in a humidified 37°C incubator with 5% CO2. Medium was 
refreshed every 2 days and starting on day 2 cells were stimulated with either 600 nM 
zoledronate, 1 µM T06 or vehicle (PBS). On the day of medium change, culture supernatant 
was collected and stored at -80oC. At the end of experiment, cells were either fixed in 4% 
paraformaldehyde (PFA) and stained for tartrate resistant acid phosphatase (TRAP) to validate 




4.2.2 Dorsal root ganglia (DRGs) culture 
Mouse DRGs (C1-L6) were isolated to generate primary neuronal cultures in Paper I. 
Dissected DRGs were kept in cold PBS prior to enzymatic digestion initially with papain (0.8 
mg/mL; 30 min at 37oC) followed by collagenase I and dispase II (12 and 14 mg/mL; 30 min 
at 37oC). Cells were then triturated in Ham’s F12 Nutrient Mixture medium supplemented with 
10% FBS, 50 U/mL penicillin and 50 µg/mL streptomycin, and seeded on glass bottom dishes 
pre-coated with poly-D-lysine and laminin. Dissociated cells were kept in a humidified 37°C 
incubator with 5% CO2 for 24 h. The following day, cells were used for calcium imaging to 
determine the effect of netrin-1 application on neuronal function.  
 
4.2.3 Macrophage culture 
For Paper III, bone marrow cells were isolated from mouse tibia and femur to generate 
primary macrophage culture. Cells were cultured in low adherence flasks in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FBS, 2mM GlutaMAX, 50 U/mL 
penicillin, 50 µg/mL streptomycin and 10 ng/mL M-CSF in a humidified 37°C incubator with 
5% CO2. Upon reaching 75-80% confluency, cells were dissociated and seeded onto 96-well 
plates in serum starved condition (medium containing 0.5% FBS). Cells were stimulated with 
1 µg/mL disulfide HMGB1 for 24 h and afterwards culture supernatants were harvested for 
measurements of inflammatory factors.  
 
4.2.4 Microglia culture  
For Study IV, both cell line and primary cultures were used for in vitro assays. The murine 
microglial cell line N13 (CD1 strain) was kindly provided by Prof. Gunnar Schulte (Karolinska 
Institutet, Stockholm, Sweden). Cells were expanded in DMEM supplemented with 10% FBS, 
100 U/mL penicillin, 50 µg/mL streptomycin and 2 mM glutamine until confluent, stimulated 
with 1 µg/mL disulfide HMGB1 in serum starved condition (0.5% FBS) and collected 6 h later 
for further analysis. 
Primary microglial cultures were generated from mouse brain and spinal cord tissues. 
Microglia were isolated and cultured using a modified version of previously described 
protocols [2; 53]. In short, tissues were mechanically dissociated followed by enzymatic 
digestion with papain for 30 min at 37oC and isolation using Percoll density gradient. Cells 
were then seeded onto culture plates precoated with poly-D-lysine and incubated for 2 h at 
37oC in microglial culture medium containing Dulbecco’s modified Eagle’s medium/nutrient 
mixture F-12 (DME/F12) supplemented with 10% FBS, 100 U/mL penicillin, 50 µg/mL 
streptomycin and 2 mM glutamine to allow for cell attachment. Subsequently, cells were serum 
starved (2% FBS) and maintained for 24 h in a humidified 37oC incubator with 5% CO2. The 
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next day, cells were stimulated with 1 µg/mL disulfide HMGB1 and collected 6 h later for 
further analysis. 
 
4.3 IMAGING ANALYSES 
4.3.1 Micro-computed tomography imaging 
For Paper I and II, bone erosion was evaluated using a micro-computed tomography (micro-
CT) imaging system. Prior to imaging, hind ankle joints were harvested from euthanized mice, 
post-fixed in 4% PFA for 48 h and transferred to 0.01 M phosphate buffered saline (PBS). 
Distal tibia, talus and calcaneus were scanned using Skyscan 1272 (Bruker) at 10 µm voxel 
size, 60 kVp/166 µA X-Ray power and 627 ms integration time. Acquired images were 
reconstructed using NRecon software (Bruker) and analyzed using CT analyzer program 
(Bruker).  
 
4.3.2 99mTc-HMDP scintigraphic imaging 
To evaluate bone remodelling in Paper I, mice were injected i.p. with 99mTc-HMDP radiotracer 
(10 MBq/mouse, Osteocys, IBA) and imaging was acquired 2.5 h post-injection. Planar 
acquisition was performed for 5 min (15% window at 140 keV) on the animal positioned in 
ventral decubitus on a parallel collimator (20mm/1.8/0.2) of a gamma camera for small animal 
(γImager, Biospace) under isoflurane anaesthesia. Quantitative analysis of bone scintigrams 
was performed with Gammavision+ software (Biospace). 
 
4.3.3 Calcium imaging  
Prior to imaging, DRG neurons were incubated in Fluo-3AM (4.4 µM, calcium indicator) for 
30 min. Cells were then washed in modified HEPES buffer (10 mM HEPES, 2mM CaCl2, 
3mM KCl, 145 mM NaCl, 2mM MgCl2, 10 mM glucose, pH 7.4, referred as EC solution) and 
placed in a recording station on Zeiss LSM800 confocal microscope. Calcium imaging was 
performed with argon laser (488 nm excitation) and 20x objective lens. The change in emission 
(560 nm), i.e. binding of intracellular calcium to Fluo-3 AM was measured every 2.5 sec using 
a photomultiplier tube. Mouse recombinant netrin-1 (0.2, 2 and 8 μg/mL) was directly applied 
using a pipette to the cells and imaging was performed for 16 min. Application of EC solution 
alone was used as control. KCl (50 mM) was applied at the end of each experiment to detect 
functional neurons. Acquired images were analyzed by ImageJ. Image analysis is described in 





4.4 MOLECULAR ANALYSES 
4.4.1 Quantitative polymerase chain reaction  
Flash frozen tissues (ankle joints, L3-L5 DRGs and L3-L5 spinal cords) and cultured cells 
(osteoclasts and microglia) were homogenized in TRIzol reagent. mRNA was extracted 
followed by cDNA synthesis according to the manufacturer’s protocol. Quantitative 
polymerase chain reaction (qPCR) was performed using predeveloped Taqman primers listed 
in Table 6. For Paper I and III, threshold cycle values for each sample were used to calculate 
the number of cell equivalents in the test samples using the standard curve method (215). The 
housekeeping genes Hprt1 or Rplp2 values were used to normalize the data, which were then 
plotted as relative expression units or percentage change to the control group. In Paper II, gene 
expression was analyzed according to the ΔΔCt method and data are presented as fold change 
to the housekeeping gene Hprt1. 
 
Table 6. List of Taqman primers  
Gene  Taqman primer Paper 
Aak1 AP2-associated protein kinase 1 Mm01183675_m1 II 
Acp5 Acid phosphatase 5, tartrate resistant Mm00475698_m1 I 
Ap2m1 Adaptor related protein complex 2 subunit  
mu 1 
Mm05884025_g1 II 
Asic3 Acid-sensing ion channel 3 Mm00805460_m1 I 
Ccl2 C-C motif chemokine ligand 2 Mm00441242_m1 III, IV 
Cd11b (Itgam) Cluster of differentiation molecule 11B Mm00434455_m1 III 
Cd34 Cluster of differentiation molecule 34 Mm00519283_m1 III 
Clcn7 Chloride channel 7 Mm00442400_m1 I 
Cox2 Cyclooxygenase 2 Mm00478374_m1 III 
Ctsk Cathepsin K Mm00484039_m1 I 
Cxcl1 Chemokine (C-X-C motif) ligand 1 Mm04207460_m1 III 
Cxcl2 Chemokine (C-X-C motif) ligand 2 Mm00436450_m1 III 
Hmgb1 High mobility group box 1  Mm00849805_gH III 
Hprt1 Hypoxanthine phosphoribosyl transferase 1 Mm03024075_m1 I-IV 
Il1b Interleukin 1b Mm00434228_m1 III-IV 
Il6 Interleukin-6 Mm00446190_m1 III-IV 
Mpo Myeloperoxidase Mm01298424_m1 III 
Ngf Nerve growth factor Mm00443039_m1 III 
Ntn1 Netrin-1 Mm00500896_m1 I 
Pecam1 Platelet endothelial cell adhesion molecule 1 Mm01242576_m1 I 
Rplp2 60S acidic ribosomal protein P2 Mm00782638_s1 I-III 
Sema4d Semaphorin 4D Mm00443147_m1 I 
Tcirg1 V-type proton ATPase 116 kDa subunit a 
isoform 3 
Mm00469406_m1 I 
Tlr4 Toll-like receptor 4 Mm00445273_m1 III 
Tnf Tumor necrosis factor Mm00434258_m1 III-IV 
Trpv1 The transient receptor potential cation channel subfamily 






Mice were deeply anesthetized in isoflurane and transcardially perfused with PBS followed by 
4% PFA. For Paper I, hind ankle joints were harvested, postfixed 48 h in 4% PFA and 
decalcified 4-5 weeks in 10% ethylenediaminetetraacetate (EDTA) decalcification solution. 
The decalcified joints were dehydrated using 70% ethanol and xylene followed by embedding 
in paraffin. Sagittal sections (5 µm) were cut using a rotary microtome. Prior to labelling, 
sections were deparaffinized, blocked for endogenous peroxidase and subjected to overnight 
antigen retrieval in Tris-acetate buffer, pH 6 at 60oC. Sections were then incubated with 5% 
normal goat serum in 0.2% Triton X-100 PBS to reduce non-specific binding and labelled with 
the appropriate primary antibodies listed in Table 7. Alkaline phosphatase-conjugated anti-
rabbit IgG (1:500) was used for secondary labelling followed by visualization using liquid fast-
red substrate kit. Sections were counterstained with Mayer’s hematoxylin and mounted in 
Aquatex mounting medium. Histomophometrical analyses are outlined in details in Paper I. 
In Paper IV, lumbar spinal cord (L1-L6) tissues were dissected, postfixed in 4% PFA for 12-
20 h and cryoprotected in 20% sucrose. Tissues were then embedded in OCT and cut into 20 
µm sections. Sections were incubated in 5% normal goat serum in 0.2% Triton X-100 PBS to 
block non-specific bindings, followed by primary antibodies listed in Table 7. Afterwards, 
sections were labelled with the respective secondary antibodies. Tyramide signal amplification 
(TSA) was performed to enhance visualization. Stained sections were then mounted in Prolong 
Gold antifade mountant.  
 
Table 7. List of primary antibodies used for immunohistochemistry  
Primary antibody Vendor/catalog Dilution Paper 
Rabbit anti-cathepsin K OriGene, TA318059 1:100 I 
Rabbit anti-CD31 Abcam, ab124432 1:250 I 
Rabbit anti-PGP9.5 Cedarlane, 184 1:500 I 
Rabbit anti-Iba1 Wako, 019-19741 1:2000 IV 
 
4.4.3 In situ hybridization 
Paraffin-embedded sections were in situ hybridized using a modified version of the ACD 
RNAScope 2.0 high-definition procedure to detect mRNA expression of Acp5 in Paper I. In 
brief, sections were incubated with pretreatment 1 for 10 min at room temperature, pretreatment 
2 for 15 min at 85oC and pretreatment 3 using a pepsin treatment (10% diluted in RNase-free 
water) for 20 min at 40oC. The subsequent hybridization and amplification were performed 
according to the manufacturer’s protocols, followed by incubation in digoxigenin (DIG)-
labeled tyramide (1:200, Perkin Elmer) and labelling with alkaline phosphatase-conjugated 
anti-DIG FAB fragments (1:1000, Roche). Sections were then visualized with liquid permanent 
red, counterstained with Mayer’s hematoxylin and mounted in Aquatex mounting medium. 
Histomophometrical analyses are outlined in Paper I.  
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4.4.4 Western blot 
Proteins from cell culture in Paper I and DRG or spinal cord tissues in Paper II and IV were 
separated using gel electrophoresis and transferred to nitrocellulose membrane. Non-specific 
binding sites were blocked with 5% non-fat milk in Tris based-buffer (50 mmol/L Tris-HCl 
and 6 mmol/L NaCl with 0.1% Tween 20). Consequently, membranes were incubated 
overnight with primary antibodies (Table 8) followed by the appropriate horseradish 
peroxidase (HRP)-conjugated secondary antibodies. Chemiluminescent reagent was used to 
visualize immunopositive bands detected on ChemiDoc Imaging System. Immunopositive 
bands were normalized to the bands of the protein reference (GAPDH or b-actin), and results 
are presented as percentage change to the respective control group. 
 
Table 8. List of primary antibodies used for Western Blot  
Primary antibody Vendor/catalog Dilution Paper 
Goat anti-A1AT R&D systems, AF2979 1:2000 IV 
Rabbit anti-AAK1 Abcam, ab59740 1:1000 II 
Rabbit anti-AP2M1 Abcam, ab75995 1:1000 II 
Rabbit anti-pAP2M1 (T156) Abcam, ab109397 1:1000 II 
Mouse anti-b-actin Cell Signaling, 3700S 1:10000 I 
Sheep anti-ELA2 R&D systems, AF4517 1:1000 IV 
Mouse anti-GAPDH Abcam, ab8245 1:10000 II, IV 
Goat anti-haptoglobin ICL, GHPT-90A-Z 1:1000 IV 
Rabbit anti-netrin-1 Abcam, ab1267729 1:1000 I 
Rabbit anti-PAR2 Abcam, ab180953 1:250 IV 
Rabbit anti-STAT3 CST, 12640 1:1000 II 
Rabbit anti-pSTAT3 (Y705) Millipore, 630098 1:1000 II 
Rabbit anti-pSTAT3 (S727) CST, 9134 1:1000 II 
 
4.4.5 Immunoassay 
For Paper I, serum was collected and levels of C-telopeptide of type I collagen (CTX-I) and 
propeptide of type I procollagen (PINP) were quantified using the RatLaps CTX-I and 
Rat/Mouse PINP EIA kits, respectively. Moreover for Paper I, platelet-derived growth factor 
BB (PDGF-BB) and semaphorin 4D (SEMA4D) were also quantified in osteoclast culture 
supernatant using Mouse/Rat PDGF-BB Quantikine ELISA and Mouse Semaphorin 
4D/CD100 ELISA kits, respectively. For Paper III, levels of TNF, IL-6, CCL2 and CXCL1 
were measured in macrophage culture supernatants using electrochemiluminescence (ECL) 
immunoassay kits following the manufacturer’s instructions.  
 
4.4.6 Liquid chromatography-mass spectrometry 
Liquid chromatography-mass spectrometry (LC-MS/MS) was performed in Paper IV to 
explore differential protein profile in male and female mice following i.t. injection of disulfide 
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HMGB1 with or without minocycline. Total protein was extracted from the lumbar spinal cord 
(L3-L5) with repetitive freeze/thaw process and sonication in lysis buffer (PBS with 1% SDS 
and a cocktail of protease inhibitors). Protein samples were further alkylated, reduced and 
enzymatically digested in endoproteases Lys-C and trypsin. The resulting peptide samples were 
labelled using TMT6 plex isobaric label reagent set according to the manufacturer’s 
instructions and fractionated using high pH reverse-phase liquid chromatography. Afterwards, 
the fractions were analyzed by high-resolution nano LC-MS/MS. The LC-MS/MS procedure 
are described in details in Paper IV.  
 
4.5 STATISTICAL ANALYSES 
Statistical tests were performed using GraphPad Prism. Results were analyzed using unpaired 
student’s t-test (for differences between two groups), one-way analysis of variance (for 
multiple groups), and two-way analysis of variance (for multiple group time course 
experiments). For LC/MC-MS data, statistical analyses were performed on R. Specific details 
on the data analysis can be found in Paper IV. All data are presented as mean ± standard error 




5 RESULTS AND DISCUSSION 
 
5.1 CONTRIBUTION OF OSTEOCLASTS TO REFRACTIVE PAIN IN THE 
COLLAGEN ANTIBODY-INDUCED ARTHRITIS MODEL 
Pain and inflammation in RA do not always coincide. Joint pain (arthralgia) may precede joint 
inflammation or persists even after successful anti-inflammatory treatments (86-88, 108). 
Clinical evidence shows that the presence of eroded bones in the joints can outlast disease 
activity (216, 217). However, it has not been thoroughly studied if these observations are 
coupled to persistent pain in RA. Thus, the aim of Paper I was to investigate the contribution 
of the bone degrading cells, osteoclasts, in maintaining long-lasting pain in experimental RA.  
The CAIA model (described in 2.2.4) was utilized to investigate RA-associated nociception in 
this study. An important aspect of this model from a pain perspective is that mechanical 
hypersensitivity is detected before, during and after the CII antibody-induced flare of joint 
inflammation (referred to as the late phase) (13, 75, 97, 134, 135). Additionally, histological 
signs of bone loss in the ankle joint are still present several weeks after joint inflammation has 
resolved (134). Therefore, the mechanistic link between refractive bone loss and pain in RA 
can be studied in this model.  
Micro-CT analyses confirmed that bone loss is present in the ankle joint in both inflammatory 
and late phases of the CAIA model. Intriguingly, erosive lesions were found to be most 
prominent and consistent in the calcaneus (Paper I, Figure 1). The reason for which erosions 
are inclined to certain bone compartments remains to be elucidated. A possible explanation is 
that CAIA induced changes in gait, which altered mechanical loading in a way that promoted 
bone loss prominently in the heel. Gait analyses are therefore warranted in future studies, 
though this may be difficult due to the polyarthritic feature of the model. Based on these 
observations, we focused on the calcaneus in subsequent studies.  
To identify if persistent bone loss in the CAIA model is due to constant overactivation of 
osteoclasts or is a remnant of the inflammatory processes, several experiments were carried out 
(Paper I, Figure 2). First, osteoclast numbers were determined in whole ankle joint samples 
and calcanei, which indicated that there were higher osteoclast numbers in the inflammatory 
but not the late phase. Second, assessment of serum markers for bone resorption and formation 
only revealed enhanced resorptive activity during inflammation and no changes in bone 
formation. Third, higher bone turnover was observed only in the inflammatory phase of the 
CAIA model as measured by 99mTc-HMDP scintigraphic imaging. Fourth, mRNA levels of 
genes that encode for the acidification machinery (Tcirg1 and Clcn7) were increased in the 
ankle joint in the inflammatory but not the late phase. Interestingly, there were no changes in 
expression of acid sensing receptors (Asic3 and Trpv1) in the DRGs in both phases of the CAIA 
model. Collectively, these findings show that increased osteoclast activity only coincide with 
joint inflammation and that acidification is not likely involved in mediating long-lasting 
nociception in the CAIA model.  
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In order to delineate the link between osteoclast activity and pain in the CAIA model, the effect 
of two different osteoclast inhibitors were examined: zoledronate and the cathepsin K inhibitor 
T06. None of these inhibitors elicited anti-inflammatory effects in the CAIA model or 
antinociceptive effects during inflammation (Paper I, Figure 3). Interestingly, both drugs 
reversed pain-like behavior in the late phase. Systemic chronic or short treatment with 
zoledronate alleviated mechanical hypersensitivity in the late phase (Figure 4A, B). Similarly, 
oral administration of T06 in the late phase resulted in normalization of paw withdrawal 
thresholds (Figure 4C). These results show intriguingly that while resorption is elevated during 
inflammation, blocking the actions of osteoclasts was only antinociceptive in the late phase. 
We therefore speculate that osteoclasts can drive pain signaling without resorbing bones.  
 
 
Figure 4. The osteoclast inhibitor zoledronate (zol) and T06 alleviate mechanical hypersensitivity in the late phase 
of the CAIA model. Paw withdrawal thresholds following s.c. injection of zoledronate (100 µg/kg) on days 6-56 
(A) and 43-56 (B), and oral gavage of T06 (40 mg/kg) on days 43-56 (C). Data are presented as mean ± SEM, 
n=5-11 mice/group, +p<0.05, ++p<0.01, +++p<0.001 for CAIA + osteoclast inhibitor vs. CAIA + vehicle (veh). 
Arrows represent drug delivery. Adapted from Paper I, Figure 3.  
 
Several reports show that both zoledronate and T06 do not selectively target osteoclasts when 
it comes to pain mechanisms. Bisphosphonates were reported to act on microglia, which led to 
attenuation of pain-like behavior in the chronic constriction nerve injury model (39). However, 
microglial inhibition only reverse CAIA-induced pain-like behavior in male mice (13) and as 
female mice  were used in this study, it is unlikely that the behavioral effects of zoledronate are 
due to microglial inhibition. Studies also show that zoledronate can polarize macrophages 
towards the M1 pro-inflammatory phenotype in male rats, which if it also takes place in female 
mice, would promote nociceptor sensitization rather than reduce it (218). Furthermore, the 
pain-relieving effects of T06 have been associated with its actions in the spinal cord, though 
the cellular target was not identified (219). While it cannot be excluded that zoledronate and 
T06 have off-target effects contributing to their analgesic effects, it seems unlikely that two 
different drugs with different off-target effects would have similar antinociceptive profile. Both 
drugs lacked effect during the inflammatory phase and required 7-10 days exposure before 
reversing hypersensitivity in the late phase. In addition, as micro-CT analyses demonstrated 
that both drugs induce bone protective effects (Paper I, Figure S2), it is tempting to conclude 
that their antinociceptive effects are mediated via inhibition of osteoclasts.  















































































Emerging data show that in addition to bone resorption, osteoclasts produce factors that 
regulate inflammation (e.g. IL-8), angiogenesis (e.g. PDGF-BB) and neurogenesis (e.g. 
Sema4D, netrin-1) (7, 58, 60, 96, 220). Some of these factors have been associated with 
nociceptive signaling (7, 220). As our data did not point to the involvement of erosive activity 
and acidification in late phase CAIA, the ability of osteoclasts to mediate vascularization and 
innervation and if these processes lead to nociception were explored in this study.  
First, vascularization and innervation of the calcaneus were analyzed in the inflammatory and 
late phase of the CAIA model as well as the effect of both zoledronate and T06. Vascular and 
nerve profile densities were elevated during inflammation and remained increased in the late 
phase. Notably, these alterations were attenuated by both osteoclast inhibitors but only 
following resolution of joint inflammation (Paper I, Figure 4).  
Second, a series of in vitro experiments were conducted using mouse bone marrow-derived 
primary osteoclast culture to identify if these cells are able to produce factors that can modulate 
bone vascularization and innervation. Mature osteoclasts release PDGF-BB, Sema4D and 
netrin-1. Exposure to either zoledronate or T06 resulted in decreased PDGF-BB levels due to 
both inhibitors, while the reduction of Sema4D and netrin-1 protein levels were only achieved 
by zoledronate and not T06 (Paper I, Figure 5).  
Recent studies point to the crucial role of osteoclast-derived netrin-1 in modulating nociception 
(59, 220, 221). Thus, the involvement of this factor in CAIA-induced hypersensitivity was 
assessed. Repeated systemic injection of the anti-netrin-1 antibody (NP137) produced no 
effects on arthritis scores or pain-like behavior in the inflammatory phase (Paper I, Figure 6), 
but was antinociceptive in the late phase (Figure 5). Furthermore, in vitro calcium imaging 
experiments with primary DRG neurons demonstrated that direct netrin-1 application enhanced 
the intracellular Ca2+ signal response rate in a dose-dependent manner (Paper I, Figure 6).  
 
 
Figure 5. Netrin-1 induces pronociceptive effects in the CAIA model. Paw withdrawal thresholds following i.p. 
injection of the anti-netrin-1 antibody (NP137, 10 mg/kg) on days 43-53. Data are presented as mean ± SEM, n=9-
10 mice/group, +p<0.05, ++p<0.01, +++p<0.001, where +represents CAIA + NP137 vs. CAIA + vehicle (veh). 
Arrows represent drug delivery. Adapted from Paper I, Figure 6.  





























The findings in this study together allude to the divergent pronociceptive actions of osteoclasts 
throughout the different phases of the CAIA model (Figure 6). In addition to acidification that 
was found to be present during inflammation, the results show the possibility that osteoclasts 
exert different actions that may lead to nociception, particularly during a low bone resorptive 
state. For instance, they could i) directly activate sensory neurons through release of netrin-1 
that may bind to one of its receptors, UNC5B, which was reported to be expressed on 
nociceptors in the publicly available Pain-seq dataset (20), ii) mediate neurite growth in the 
bone, possibly through production of Sema4D and netrin-1 and (iii) promote vasculogenesis 
by secreting PDGF-BB, which in turn supports neoinnervation (222).  
 
 
Figure 6. Osteoclasts modulate different pronociceptive actions in the inflammatory and late phase of the CAIA 
model. During inflammation, resorbing osteoclasts induce acidification through release of protons that may 
activate sensory neurons by binding to acid sensing nociceptors, ASIC3 and TRPV1. Increased bone 
vascularization and innervation are also observed during this phase (right panel). In the late phase, non-resorbing 
osteoclasts release netrin-1 that could directly activate sensory neurons by binding to its receptor, UNC5B 
expressed on nociceptors or by stimulating neurite outgrowth in the bone. Non-resorbing osteoclasts can also 
release PDGF-BB and Sema4d which can increase innervation and vascularization, which also supports 
neoinnervation (left panel). Created in Biorender.com  
 
Overall, this study highlights the complexity of osteoclast activity in nociception and presents 
the concept that their pronociceptive actions are not completely coupled to resorptive activity. 
In addition, this study shows the beneficial effects of inhibiting osteoclast activity or 
nociceptive factors released by these cells for pain-like behavior in the CAIA model, especially 
in the refractive state. In a translational perspective, this study illustrates the potential use of 




5.2 BARICITINIB REDUCES REFRACTIVE PAIN IN THE COLLAGEN ANTIBODY-
INDUCED ARTHRITIS MODEL THROUGH AAK1 INHIBITION 
JAK/STAT inhibitors such as tofacitinib and baricitinib are the latest disease-modifying drug 
class to emerge for the treatment of RA. A recent Phase III clinical trial showed that baricitinib 
significantly improved joint pain and physical function in RA patients (117-119). More 
interestingly, the pain-relieving property of baricitinib on these patients was not correlated with 
its anti-inflammatory effects (118). This suggests that baricitinib is also targeting non-
inflammatory aspects of pain mechanisms and may therefore be beneficial for RA patients with 
refractive pain.  
The aim of Paper II was to characterize the antinociceptive effect of baricitinib in the CAIA 
model as well as to delineate its underlying mechanism. Originally this study was intended to 
further explore the contribution of osteoclasts in RA-induced pain as baricitinib is known to 
reduce pathological bone loss (223, 224). However, it has been shown that baricitinib does not 
directly act on osteoclasts but rather inhibits bone loss via activation of osteoblast function 
(113). Since we did not find indications of altered bone formation in the CAIA model in Paper 
I and that baricitinib did not prevent CAIA-induced bone loss (data not shown), we decided to 
examine other mechanisms for this study.  
Baricitinib significantly reduced joint inflammation in CAIA animals (Paper II, Figure 1), 
which is in accordance with animal studies showing clear anti-arthritic effects of this drug on 
rodents subjected to arthritis (113, 225). Surprisingly, baricitinib induced very modest effect 
on mechanical hypersensivity during inflammation (Paper II, Figure 1), but was considerably 
effective in reversing pain-like behavior in the late phase (Figure 7). These findings are in 
agreement with clinical evidence showing that the pain-relieving effects of baricitinib do not 
completely correlate with levels of inflammatory markers and that this drug is also beneficial 
for pain in RA patients with minimal disease activity (119, 120).  
 
Figure 7. Baricitinib reverses mechanical hypersensitivity in the late phase of the CAIA model. Baricitinib (40 
mg/kg, b.i.d) was administered per oral gavage on days 45-51. Paw withdrawal thresholds and quantification for 
area under the curve (AUC) for withdrawal thresholds of CAIA animals from days 47-51. Data are presented as 
mean ± SEM, n=5-7 mice/group, ++p<0.01, +++p<0.001 for CAIA + vehicle (veh) vs. CAIA + baricitinib (bari). 




The JAK/STAT signaling regulates multiple cytokine pathways, many of which are implicated 
in pain (122). Thus, we speculate that baricitinib blocks pain signaling through interference 
with cytokine receptor signal transduction and production. Alterations in the downstream 
STAT3 signaling have been reported in models of inflammatory and neuropathic pain (226-
228). Interestingly, we failed to find increased activation of STAT3 in DRGs or spinal cords in 
the late phase of the CAIA model, though baricitinib reduced basal levels of phospho-STAT3 
level (Paper II, Figure 2). These findings suggest that the STAT3 pathway is not the main 
target of the antinociceptive action of baricitinib in the late phase CAIA. 
In addition to JAKs, baricitinib was recently discovered as an inhibitor for the adaptor protein-
2 (AP-2) associated kinase 1 (AAK1) (123). AAK1 regulates clathrin-mediated endocytosis 
through phosphorylation of the adaptor protein AP2 on the µ subunit (encoded by Ap2m1 gene) 
(229). This finding was important for identification of potential drugs for COVID-19 as it is 
predicted that AAK1/clathrin-mediated endocytosis paves way for viral entry into the lung 
cells. Interestingly, AAK1 has also been implicated in pain and electrophysiological recordings 
showed the spinal cord as a possible site of pronociceptive action for this protein (125). Based 
on this, experiments were carried out to investigate if AAK1 is involved in the pain-modulating 
actions of baricitinib in the CAIA model.  
First, evaluating mRNA levels of Aak1 and its downstream target Ap2m1 in ankle joints, DRGs 
and spinal cords from CAIA mice showed upregulation exclusively in DRGs from the late 
phase (Paper II, Figure 3). Second, there was a differential regulation of the AAK1/AP2M1 
axis on protein levels in the late phase of the CAIA model, whereby it is induced in DRGs but 
inhibited in spinal cords. The presence of baricitinib normalized phosphorylation and protein 
expression of AP2M1 in DRGs but not in spinal cords (Table 9). While these findings indicate 
an involvement of the AAK1/AP2M1 axis in the regulation of pain in the CAIA model, the 
results point to a more prominent role of these proteins in DRGs rather than in spinal cords as 
previously suggested (125). Intriguingly, in the publicly available Pain-seq database both Aak1 
and Ap2m1 mRNA levels are upregulated in DRG neurons from models of nerve injury or 
chemotherapy-induced pain (20). This supports the hypothesis that AAK1 and AP2M1 have 
pronociceptive roles in DRGs. Thus, we speculate that there is a temporal regulation and site 
specific function of AAK1 signaling at the level of DRG compared to the spinal cord in the 
CAIA model, which will be explored in future studies.  
The downstream consequences of AAK1 activation in relation to pain remain to be elucidated. 
One group identified a possible interplay between AAK1 and the noradrenergic pain pathway 
since antagonism of a2-adrenergic signaling blocked the antinociceptive effects of AAK1 
inhibition (125). Another group reported a potential role of AAK1/AP2M1 in regulation of 
neuronal excitability as endocytosis of sodium-activated potassium channels in DRG neuronal 
cultures and spinal cord slices is mediated by the AAK1-activated adaptor protein AP2 (230). 
Though further studies are required to better understand the role of AAK1 in pain, this work 
highlights the possibility that AAK1 and clathrin-mediated endocytosis play an important role 
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in non-inflammatory hypersensitivity and the mechanisms targeted by the antinociceptive 
actions of baricitinib. 
 
Table 9. Phospho-AP2M1, APM1 and AAK1 protein levels in DRGs and spinal cords of CAIA mice 
treated with vehicle (veh) or baricitinib (bari) to saline control (adapted from Paper II, Figure 4) 
 pAP2M1 AP2M1 AAK1 
DRG    
   CAIA + veh ­ ­ = 
   CAIA + bari = = = 
Spinal cord    
   CAIA + veh ¯ = = 
   CAIA + bari ¯ = = 
 
The urgent need for identification of alternative drugs for  COVID-19 has revealed baricitinib 
as not only a classic JAK/STAT inhibitor, but also an inhibitor of other kinases. This study 
provides insights that the antinociceptive effects of baricitinib are mediated by the 
AAK1/AP2M1 axis in the DRGs. More importantly, baricitinib was able to reverse 
hypersensitivity in post-inflammatory arthritic conditions thus indicating its therapeutical 
potential for pain management in RA patients with refractive pain. 
 
5.3 SEX- AND CELL-DEPENDENT CONTRIBUTION OF HIGH MOBILITY GROUP 
BOX 1 PROTEIN AND TLR4 IN ARTHRITIS-INDUCED PAIN 
Spinal high mobility group box 1 protein (HMGB1) serves important roles in pain processing 
in the CAIA model (75), however the involvement of peripheral HMGB1 has not yet been 
examined. Paper III aimed to investigate the role of peripheral HMGB1 in RA-induced pain 
and explore if sex contributes differentially to nociception in this context. We reasoned that 
examination of sex differences are especially important in studies exploring links between 
HMGB1 and pain as HMGB1 is a ligand for TLR4 and the role of TLR4 in pain has been 
associated with sex dimorphism in rodents (70). 
In accordance with previous work (75), no significant differences were observed in terms of 
arthritis severity and mechanical hypersensitivity between male and female mice subjected to 
CAIA. Following CAIA induction, Hmgb1 mRNA levels were increased in the ankle joints in 
both sexes (Paper III, Figure 1). Intriguingly, while inhibiting the action of peripheral HMGB1 
with the neutralizing antibody 2G7 produced no anti-inflammatory effects in males and females 
(Paper III, Figure 1), pain-like behavior was reversed in only male mice (Figure 8). This result 
is rather surprising given that systemic TLR4 antagonist produced beneficial effects in both 
sexes of mice injected with formalin (78). One possible explanation is that HMGB1 may act 
through other receptor systems which have more prominent roles in females than males. Future 





Figure 8. Anti-HMGB1 antibody (2G7) reverses CAIA- induced pain-like behavior in male but not in female 
mice. Mechanical hypersensitivity (A, B) following s.c. injection of 2G7 (100 µg/mouse) or vehicle once a day on 
day 12-16 in male and female mice. Data are presented as mean ± SEM, n=6 mice/group, *p<0.05, **p<0.01 for 
CAIA + 2G7 vs. CAIA + vehicle group. Adapted from Paper III, Figure 1. 
 
The above results prompted us to further characterize the pronociceptive role of HMGB1 in 
the ankle joint. First, we observed injection of disulfide, but not all-thiol, HMGB1 into the 
ankle joint evoked mechanical hypersensitivity in male and female mice (Paper III, Figure 3). 
This indicates that the ability of local HMGB1 in the joint to produce nociception is redox-
dependent rather than sex-dependent. Second, we showed that disulfide HMGB1 stimulation 
led to greater inflammatory response in male compared to female mice as observed by 
assessment of cytokine and chemokine expression in the joint following injection (Paper III, 
Figure 4) as well as release of these factors in cultured macrophages (Paper III, Figure 6). 
Third, we found indications that these processes could be mediated by resident macrophages 
in the joint, which appeared to be more strongly implicated in males than females. This is 
because blockade of macrophages with minocycline protected male but not female mice from 
developing disulfide HMGB1-induced hypersensitivity (Paper III, Figure 7). The results are 
aligned with previous studies showing that while TLR4 agonist in the periphery induced 
nociceptive behaviors in both sexes (70), TLR4 activation led to a more pronounced 
inflammatory response in males versus females (231, 232).  
Having observed the involvement of immune cells in HMGB1-induced pain, we asked the 
question if HMGB1 can directly activate nociceptors since TLR4 is also expressed in these 
cells (25). Using mice with specific TLR4 deletion in myeloid cells including macrophages 
(LysM-TLR4fl/fl) and nociceptors (Nav1.8-TLR4fl/fl), we found that TLR4 ablation in myeloid 
cells induced greater protection against HMGB1-induced hypersensitivity in males compared 
to females (Figure 9A, B). However, deletion of TLR4 on sensory neurons prevented HMGB1-
induced pain-like behavior in both sexes (Figure 9C, D). These results did not point to an 
exclusive cell-specificity of HMGB1 actions in the joint, but it demonstrated a greater 
contribution of myeloid cells possibly macrophages to nociceptive mechanisms in males 





Figure 9.  TLR4 deletion in nociceptors prevents HMGB1-induced hypersensitivity in both sexes while depletion 
in myeloid cells only protects males. Withdrawal response and hyperalgesic (HI) index (0-6h) after i.a. injection 
of disulfide HMGB1 (dsHMGB1, 1 µg/mouse) or PBS (vehicle) in mice with TLR4 deletion in nociceptors (Nav 
1.8-TLR4fl/fl) (A, B) or myeloid cells (LysM-TLR4fl/fl) (C, D). Data are presented as mean ± SEM, n=5-8 
mice/group, *p<0.05, **p<0.01, ***p<0.001 for comparisons with the vehicle group. Adapted from Paper III, 
Figure 8. 
 
With respect to the involvement of macrophages in HMGB1-induced pain, we cannot exclude 
the contribution of other cells. This is because minocycline, which was used to block activation 
of resident macrophages in the periphery, is known to have inhibitory effects on T cells and 
neurons (22). In addition, the LysM promoter used to delete cell-specific TLR4 in mice are not 
exclusive to macrophages, but also expressed by other myeloid cells (233). Importantly, 
however, we show that disrupting the activation of immune cells was more effective in 
protecting males than females from developing HMGB1-induced pain-like behavior.  
On the subject of RA-induced pain, only few studies have made side-by-side comparisons 
between male and female mice (13, 75, 234, 235). Herein, we demonstrate that while peripheral 
disulfide HMGB1 can induce joint hypersensitivity in both male and female mice, HMGB1-
TLR4 interactions in immune cells contributes more prominently to this mechanism in male 
mice. Though more studies are needed to uncover the underlying mechanism, this work 





5.4 SEX-DEPENDENT ROLE OF MICROGLIA IN DISULFIDE HIGH MOBILITY 
GROUP BOX 1 PROTEIN-MEDIATED MECHANICAL HYPERSENSITIVITY  
As stated above, HMGB1 is regarded as a crucial player in the spinal regulation of chronic 
pain. Earlier work showed that HMGB1-induced microglial activation in the spinal cord is 
associated with pain-like behavior observed in the animals (75). However, sex dimorphism was 
not addressed in this study. Since Paper III indicated a sex-dependent role of HMGB1 in the 
periphery and several studies showed the role microglia in pain to be sex-specific (12, 13), the 
aim of Paper IV was to investigate if disulfide HMGB1 induces nociception via microglial 
activation in a sex-dependent fashion.  
Following spinal injection of disulfide HMGB1 in both male and female mice, microglia 
displayed signs of activation to the same extent in both sexes in the form enlarged cell bodies 
and Iba-1 immunoreactivity (Paper IV, Figure 1). This supports previous studies showing 
equal levels of microglial activation in both sexes subjected to nerve injury (70, 236). Another 
feature of activated microglia is the production of pro-inflammatory factors (237, 238). 
Intriguingly, direct stimulation of disulfide HMGB1 on cultured microglia induced more 
pronounced mRNA expression of inflammatory factors in male- versus female-derived cells 
(Paper IV, Figure 2). This shows that the proinflammatory response of microglia to HMGB1 
stimulation is sex-dependent which is in congruent with previous work showing that TLR4 
activation by LPS evokes higher mRNA levels of Il1b in male microglia (239). 
To delineate if spinal microglia display a sex-dependent role in pain mechanisms mediated by 
HMGB1, microglia activation was inhibited by either genetic or pharmacological 
manipulations. First, specific TLR4 deletion in myeloid-derived cells including microglia 
(LysM-TLR4fl/fl) in the spinal cord protected male but not female mice from developing 
hypersensitivity due to intrathecal disulfide HMGB1 (Figure 10A, B). Second, co-injection of 
minocycline (microglial inhibitor) with disulfide HMGB1 produced antinociceptive effects 
only in male mice (Figure 10C, D). Both of these results indicate a response that follows a 
sexually dimorphism pattern.   
The use of LysM-Cre to target microglia has been debated since LysM is also expressed by 
other myeloid cells such as macrophages (205) and expressed only in a subpopulation of 
microglia (20-45% of total population) (240, 241). However, several studies including our 
own show that microglia are the predominant myeloid cells present in naïve spinal cord (13, 
242, 243), and therefore TLR4 depletion in LysM-TLR4fl/fl mice is highly specific for 
microglia. Notably, targeting this subset of microglia was sufficient enough to reveal sex 
dimorphism in our study. Furthermore, results from the minocycline experiments have to be 
treated with cautions since this drug has well-documented anti-inflammatory actions that are 
not restricted to microglia, but also T cells, neutrophils, neurons and astrocytes (22). 
Accumulating evidence, however, shows that minocycline produces sex-dependent 
antinociceptive effects on different models of pain (12, 13, 79, 244-246) as presented here, 





Figure 10. Blockade of microglial activity is antinociceptive for male but not female mice injected with disulfide 
HMGB1 (dsHMGB1) into the spinal cord. Withdrawal response after i.t. injection of dsHMGB1 (1 μg/mouse) in 
male and female mice lacking TLR4 in microglia (LysM-TLR4fl/fl) (A, B). Withdrawal response before and after 
i.t. injection of of dsHMGB1 (1 μg/mouse) mixed with minocycline (30 μg/mouse, microglial inhibitor) or 
dsHMGB1 (1 μg/mouse) mixed with vehicle (PBS), as well as 6 h after the second day i.t. injection of minocycline 
(30 μg/mouse) or vehicle in male and female mice (C, D). Data are presented as mean ± SEM, n=4-8 mice/group, 
*p<0.05, **p<0.01, ***p<0.001 for comparisons with the vehicle group. Adapted from Paper IV Figure 3.  
 
In-depth proteomics of the spinal cord with LC/MS-MS was therefore used to further explore 
the downstream proteins regulating sex differences in response to minocycline treatment. An 
interesting pattern observed among the proteins identified is the dominance of anti-
inflammatory and antinociceptive factors, which were upregulated in the male mice group that 
received minocycline treatment, especially three isoforms of alpha-1-antitrypsin that were 
differentially expressed between sexes (Paper IV, Figure 5).   
We were particularly interested in exploring the role of alpha-1-antitrypsin (A1AT) in 
nociception since an earlier report has indicated an antinociceptive role of A1AT in an 
osteoarthritis-induced pain model (247). Notably, alpha-1-antitrypsin partially protected male 
but not female mice from developing hypersensitivity following co-injection with HMGB1 
(Table 10). Previous reports show that the antinociceptive effects of alpha-1-antitrypsin are 
mediated by inhibition of both neutrophil elastase and proteinase-activated receptor 2 (PAR2) 
(247, 248). Interestingly, our data do not completely support this linkage as suppression of 
neutrophil elastase did not block the development of HMGB1-induced hypersensitivity in both 
male and female mice (Table 10). On the other hand, global PAR2 deletion prevented disulfide 
HMGB1-induced pain in both sexes (Table 10). While the mechanism is still not clear, we 
hypothesize that since alpha-1-antitrypsin can inhibit other proteases (249), blocking elastase 
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was not sufficient to dampen the pronociceptive effects of HMGB1. Furthermore, we speculate 
that disulfide HMGB1 may activate different signaling axis in male and female mice which 
may converge in PAR2, and that this pathway was affected by minocycline treatment in male 
mice.  
 
Table 10. The effect of alpha-1-antitrypsin, neutrophil elastase inhibition and PAR2 depletion on 
HMGB1-induced pain-like behavior in male and female mice (Adapted from Paper IV, Figures 6, 7) 
 Male Female 
Alpha-1-antitrypsin Partial protection No protection 
Sivelestat (neutrophil elastase 
inhibitor) 
No protection No protection 
PAR2 knock-out Full protection Full protection 
 
Taken together, the findings of this study support previous work showing a sexually dimorphic 
role of microglia in pain processing. Of importance, the proteomics approach has uncovered 
an interesting pattern of protein expression, which suggests differential microglial function 
between male and female mice in response to minocycline. That is, minocycline elevates anti-
inflammatory and antinociceptive factors in only male mice, but that there may be points of 
convergence in both sexes. Most certainly, several of the identified proteins represent intriguing 




6 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Pain is a debilitating feature of RA and the multifactorial nature of its pathogenesis has hindered 
effective pain managements in patients. This thesis has focused on dissecting the underlying 
mechanisms of pain in RA, in particular the chronic state. Overall, this thesis proposed three 
novel mechanisms that may regulate nociception in RA (Figure 11).  
 
 
Figure 11. Bone and neuroinflammation-associated mechanisms mediate pain in RA. Using the disease-relevant 
CAIA model, three novel mechanisms driving long-lasting pain in RA are proposed in this thesis. These 
mechanisms include: (i) the role of osteoclasts (OC) in nociception that is independent of their resorptive activities; 
(ii) the role AAK1/AP2M1 in clathrin-mediated endocytosis (CME) that is inhibited by the JAK/STAT inhibitor 
baricitinib; (iii) the role of peripheral and spinal disulfide HMGB1 (dsHMGB1) that regulate sex-specific pain 
mechanisms. Created in Biorender.com. 
 
The first mechanism proposed is the important contribution of osteoclasts in RA-induced pain, 
which is independent of their resorbing actions, as described in Paper I. In prospective, the 
findings in this study imply for the potential use of osteoclast-blocking as therapeutic 
intervention for RA patients with refractive pain. While this is possible with osteoclast 
inhibitors that have broad mechanism of actions, this study also investigated the possibility that 
similar outcomes can be achieved by inhibiting nociceptive factors specifically released by 
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osteoclast such as netrin-1. An anti-netrin-1 antibody is currently undergoing Phase II clinical 
trials for treatments of gynecological cancers (250, 251) and it has shown an excellent safety 
profile that may be compatible with examining the potential of netrin-1 inhibition in RA 
patients with chronic pain. In order to reach these goals, future studies are warranted to further 
explore the translational perspective of these findings. For instance, evaluating factors that we 
found to be produced by osteoclasts in human samples would be relevant.  
Expanding on the knowledge of refractive pain in RA, Paper II proposed AAK1 and AP2M1 
to be novel players in the scene. While more studies are needed to understand the downstream 
consequence of AAK1/AP2M1 activation, this study presents the important observation that 
baricitinib being an inhibitor for this pathway is more effective in counteracting pain sensitivity 
in a non-inflammatory state. As clinical evidence also points to the non-inflammatory actions 
of baricitinib as a pain-relieving drug in patients (118, 120), subsequent studies are required to 
understand if this drug can be used to treat patients with remaining pain. In addition, this study 
points to AAK1 and AP2M1 as potential targets for pain in RA, especially as the AAK1 
inhibitor LX9211 is now currently clinically assessed for indications of neuropathic pain (252, 
253). Whilst the role of clathrin-mediated endocytosis is relatively unexplored in pain studies, 
a recent report on primate sensory neurons shows that genes associated with this mechanism 
are identified in peptidergic neurons and highly correlates to different human chronic pain 
conditions (254). This may suggest that clathrin-mediated endocytosis is an integral aspect of 
pain signaling, which should be further dissected.  
In Paper III and IV, it was proposed that disulfide HMGB1-TLR4 signaling in different cells 
may lead to sex-specific differences in pain mechanisms. In the periphery, Paper III showed 
the importance for this molecular interaction in nociceptors for both males and females, while 
interactions in immune cells were more important for males. In the spinal cord, Paper IV 
illustrated that activation of TLR4 by disulfide HMGB1 in microglia played greater roles for 
pain signaling in male versus female mice. Though this data is important from a translational 
perspective as it points to HMGB1 as a potential target for pain relief, it also brings light that 
such approach would require deepening our perception of sex differences associated with 
TLR4. Together, these findings highlight the importance of including both sexes and the 
perception that the effect of blocking HMGB1 on one sex does not always translate into the 
same effect on the other sex. 
An important aspect of this thesis that remains to be elucidated is the notion if the proposed 
mechanisms in Paper I-IV are somewhat linked to one another. Thus, the following questions 
are relevant to address for future research: 
Are there links between endocytosis, vascularization and innervation in the CAIA model? 
We have preliminary data indicating that low dose baricitinib reduced Sema4d and Ntn1 
mRNA levels in ankle joints from late phase CAIA mice. Previous studies show that AAK1 
inhibits neuregulin-1 (NRG1)-mediated neuritogenesis (255). While one could argue that this 
contradicts our findings, it is not known if NRG1 is involved in innervation in the CAIA model 
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and if AAK1 produces different effects on netrin-1 activity. Thus, exploring the connection 
between AAK1, netrin-1 and innervation may reveal if the antinociceptive actions of baricitinib 
is also through modulation of AAK1-mediated innervation.  
Recent studies show that SARS-Cov-2 spike protein inhibits vascular endothelial growth 
factor-A/neuropilin-1-receptor (VEGF-A/NRP1) signaling to dampen pain and may therefore 
increase disease transmission in asymptomatic individuals (256). Besides being pronociceptive 
factors, VEGF-A/NRP1 are also angiogenic factors. Interestingly, it was shown that VEGF-A 
induces NRP1 endocytosis, which is essential for activation of nociceptive signaling (257). 
Therefore, it may be possible that in addition to supporting neoinnervation, angiogenic factors 
could also control endocytic trafficking of proteins that are involved in pain signal 
transmission, and this warrants further investigations. 
Does HMGB1 regulate the pronociceptive actions of osteoclasts?  
HMGB1 is known to promote osteoclast activity (170). Although not studied within this thesis 
work, our laboratory is currently investigating how osteoclasts and HMGB1 may be coupled 
to pain in arthritis conditions. Our preliminary data indicates that HMGB1 promotes the 
production of inflammatory mediators in differentiating osteoclasts, including IL-8. As 
HMGB1 is involved in angiogenesis and neurite growth (258, 259), an important question to 
be addressed is if HMGB1 modulates the capability of osteoclasts to induce these processes.  
Are there sex-specific differences in the antinociceptive effects of osteoclast inhibitors or 
baricitinib?  
While sex differences were not examined in Paper I and II, the CAIA model used for these 
studies shows higher arthritis incidence in females than males (13). As this reflects the clinical 
situation in which more women suffer from RA than men, the findings are important for a large 
proportion of RA patients. Future investigations are however still warranted to identify if 
similar mechanisms are present in the male counterparts.  
In conclusion, as pain remains to be a significant problem for many patients with RA, it is 
imperative to increase efforts to improve pain management. The results presented in this thesis 
have shed new lights on the role of osteoclasts, AAK1/AP2M1 and HMGB1 that may be 
pertinent to long-lasting pain in RA. While more research is needed to grasp the exact 
mechanisms of pain in RA, this work is a step forward to advance more effective pain 
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